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ABSTRACT
 
Thyroid hormone(T3)inducesGLUT4transporters and restores normal membrane-

bound GLUT4 quantities in adipocytes and myocytes,induces thermogenesis, improves
 
glycemic status, and normalizes the metabolism ofTj-resistant db/db mice. The effect of
 
T3onGLUT4transporter expression in +/db and db/db mice wasinvestigated by comparing
 
the cytoplasmic and membrane bound GLUT4in adipocytes and myocytesfrom vehicle-

treated and Tj-treated animals, Total GLUT4in adipocytes ofvehicle-treated db/db mice
 
was50%of+/db mice(D.886±0.31 vs. 1.99±0.37OD units,p<0.01)but could be restored
 
to normal(1.928±0.21 OD units)with 500 ng T3/g BW. Cytoplasmic GLUT4 content of
 
adipocytes in vehicle-treated db/db mice was50%less than +/db animals(0.624±0.22 vs.
 
1.488±0.36 OD units, p<O.Ol). However, T3 treatment (500 ng/g BW)increased
 
cytoplasmic GLUT4in db/db mice beyond that of+/db xmcQ(1.50±0.22 vs. 1.04±0.26 OD
 
units, p<0.01). The GLUT4 plasma membrane fraction in db/db mice was also 50%less
 
than +/<iZ> animals(0.262±0.09 vs.0.502±0.06 OD units, p<0.05)but approximated that of
 
+/db mice with500 ng T3/gBW dose(0.428±0.28 vs. 0.406±0.20 OD units, p>0.05). A
 
disproportionate depletion ofcytoplasmic GLUT4 m' db/db mice and a concomitant increase
 
in plasma membrane GLUT4 indicates that T3 regulates GLUT4 translocation from the
 
cytoplasm to the plasma membrane. Diabetic mice have reduced GLUT4expression in the
 
plasma membrane whichlikely influences glucose uptake and contributes to hyperglycemia
 
in this model. However,thyroid hormone increases GLUT4expression and translocation
 
in adipose tissue of mice.
 
Ill
 
Total myocyte GLUT4contents are similar in +/<iZ> and dh/db mice. T3treatment
 
increased these quantities in both +/(i^(0.58±0.07 vs.0.744±0.04OD units, p<0.05)and
 
db/db (0.572±0.06 vs. 0.656±0.04 OD units, p<0.05) mice. The cytoplasmic GLUT4
 
quantity in vehicle-treated db/db mice was greater than +/db mice (0.326±0.05 vs.
 
0.268±0.05 OD units, p<0.05)while the membrane quantity in db/db mice was less than
 
+/db mice(0.246±0.03 vs. 0.312±0.06 OD units, p<0.05). Vehicle-treated db/db mice
 
possess total GLUT4 quantities equivalent to +/db mice, but have reduced plasma
 
membrane quantities which indicate disproportionate distributions of the GLUT4
 
transporter. However,T3treatment(500 ng/gBW)mdb/db mice,decreased cytoplasmic
 
GLUT4content and increased plasma membrane fraction which suggests that T3 promotes
 
GLUT4translocation.
 
T3-induced thermogenesis occurred in both +/(iZ> and db/db mice and the
 
temperature increase in db/db mice paralleled the appearance ofGLUT4 in the plasma
 
membrane ofmyocytes. A48%reduction in serum glucose concentrations was also found
 
in db/db xmce m response to T3(592.0±126 vs. 334.9±62.9 mg glucose/dL, p<0.01).
 
Respiratory quotient(RQ)values indicate, however, a shift to fat catabolism with T3
 
treatmentmdb/db rmce(0.74±0.03). The apparent metabolic substratein Tg-treated db/db
 
mice is not consistent with increased membrane-bound GLUT4 transporters facilitating
 
skeletal muscle glucose uptake which would lead to decreased serum glucose
 
concentrations. Enhamced glucose uptake by another tissue is suggested. This is the first
 
studyto show that T3 restores GLUT4translocation in animals and may explain the
 
glucose transport defect underlying NIDDM.
 
IV
 
This project would not have been accomplished without the help and support of
 
many people. Although 1 cannotthank every person,1 would like to extend my gratitude
 
to afew people. Ithank mythesis committee Dr. Richard Fehn,Dr. Dave Polcyn,and Dr.
 
Michael Loik for their project guidance and assistance in preparing the thesis manuscript.
 
I especially would like to thank Dr. Richard Fehn,my major advisor,for all the time and
 
effort he invested in me throughout the years. I sincerely appreciate his guidance,
 
encouragement,and mentoring,but most ofall his friendship.
 
Very specialthanksgo to John Tometich for his continued love and support during
 
my graduate years. I sincerely thank him for his continued encouragement and patience
 
tliroughout the course ofmy thesis project and thesis writing. I appreciate all that he has
 
done however,there are not enough wordsto describe my gratitude.
 
Dr. Stuart Sumida and Dr.BethRegaeach deserve special thanksfor their friendship
 
and support throughout my graduate training as well as for continued use of the
 
photography equipmentto makethose "last-minute" slides.
 
I cannotthank Dr. Colleen Talbot enough for serving as an adjunct member ofmy
 
committee and for the invaluable assistance with preparation ofmythesis. I would like to
 
thank both Dwight Gallo and MikeMahoneyfor their technical support since they were the
 
ones who always ensured that the equipment wasfunctioning and that my supplies were
 
ordered. In addition,I thank Carol Smith for her continued assistance throughout the years.
 
My parents, brother, sister, and grandmother also deserve very special thanks for
 
their continued love, prayers, and financial support throughout my education. I appreciate
 
all oftheir encouraging words during this time ofmy life as well understanding the wayI
 
am. I could not have done this without them. Thank you so much for everything. I am
 
most grateful to all ofthese individuals and many others who assisted with this project.
 
This project was partially funded by CSUSB ASI graduate research funds, the
 
Galifomia Pre-Doctoral Fellowship, the CSUSB Graduate Equity Fellowship, and the
 
National Hispanic Scholarship Fund.
 
VI
 
TABLEOF CONTENTS
 
ABSTRACT •••■ - Ui 
ACKNOWLEDGEMENTS v 
LIST OF TABLES iN 
LIST OF FIGURES ' v: ^ >X,;' 
CHAPTER ONE: INTRODUCTION 
Overview ofDiabetes Mellitus . . 
Diabetic Mouse Model 3 
Facilitative Glucose Trarisportefs 5 
GLUT4 VesicularTrafficking^ ^^ ^ ^.^..v..^ 
iGLUT4 Studies U 
NIDDM and Obesity „ 13 
Glucoregulatory and ThyroidHormones 14 
ProposedEffect of ThyroidHoromone on GLUT4 Expression ...... 17 
CHAPTER TWO: MATERIALS AND METHODS 
Animals and Tissues .. 22 
Metabohc RateDeteiminations and Temperature Studies 
GLUT4 Fractionation Studies 23 
GLUT4 Quantification 24 
Serum Glucose Determination 25 
Statistical Analysis 25 
Vll 
CHAPTERTHREE: RESULTS
 
GLUT4Fractionation Characterization 26
 
Core and Radiant Temperature Studies 38
 
Serum Glucose Determination 46
 
Respiratory Quotient Determination 47
 
CHAPTERFOUR:DISCUSSION 49
 
Appendix 1. 64
 
Appendix 2. ! 65
 
REFERENCES 67
 
Vlll
 
20 
LIST OF TABLES
 
Table 1. CD readings ofadipocyte cytoplasmic and membrane-

bound GLUT4 proteins in vehicle-treated(0 ng Tj/gBW)
 
and Tj-treated(500 ng/gBW)normal(+M»)and diabetic
 
{db/db)mice 

IX
 
LIST OFFIGURES
 
1. 	Total GLUT4transporter contentin adipocytes ofnormal(+/<i&)
 
and diabetic{dh/dh)mice treated with T3(0, 100,200,
 
and 500 ng/gBW) 26
 
2. 	 Cytoplasmic GLUT4transporter content in adipocytes ofnormal
 
(+/<i3)and diabetic mice treated with T3(0, 100,200,
 
and 500 ng/gBW) . 28
 
3. 	 GLUT4 quantity associated with plasma membrape ofadipocytes
 
ofnormal(+/£/&)and diabetic rnice treated with T3(0, loo,200,
 
and 500 ng/g BW) . 29
 
4. 	Fraction ofGLUT4transporters associated with plasma membrane
 
ofadipocytes ofnormal /db)and diabetic{dh/dh)mice treated with
 
T3(0, 100,200,and 500 ng/g BW) 30
 
5. 	 Total GLUT4transporter content in myocytes ofnormal {- /dh)
 
and diabetic{dh/dh)mice treated with T,(0, 100,200,and
 
500 ng/g BW) . 32
 
6. 	 Cytoplasmic content ofGLUr4transporters in myocytes of
 
normal( /dh)and diabetic(dh dh)mice treated with T3(0, 100,
 
200,and 500 ng/gBW)^ ; _ ............ 34
 
7. 	GLUT4 quantity associated with plasma membrane ofmyocytes
 
ofnormal(\/dh)and diabetic{dh/dh)mice treated with T,(0, 100,
 
200,and 500 ng/gBW) ; 35
 
8. 	Fraction ofGLUT4 associated with plasma membrane ofmyocytes
 
ofnormal(-/dh)and diabetic(dh/dh)mice treated with T3(0, 100,
 
200,and 500 ng/gBW) 36
 
9. 	 Core bodytemperatures ofnormal( /dh)and diabetic(dh/dh)mice
 
treated with T3(0, 100,200,and 500 ng/g BW) 38
 
10. 	Daily core body temperatures ofvehicle-treated nonnal(\/dh)
 
and diabetic(db/dh)xmcQ 
 39 
11. Daily core body temperatures ofnormal( dh)and diabetic{db/db) 
mice treated with 100 ng Tj/gBW 40 
12. Daily core body temperatures ofnormal(+/<iZ))and dia.betic (i/Z»/<i&) 
mice treated with 200 ng Tj/gBW 41 
13. Daily core body temperatures ofnormal 
mice treated with 500 ng Tj/gBW 
and diabetic 
42 
14. Radianttemperatures ofnormal{+/db)mA diabetic 
treated with 13(0, lOO,200,and 500 h^gBW) 
mice 
43 
15. Radianttemperatures ofnormal{+/db)and diabetic(db/db)rmcQ 
treated with 200 ng Tj/gBW 44 
16. Radianttemperatures ofnormal(+/<i&)and diabetic 
treated with 500 ng Tj/gBW 
mice 
45 
17. Serum glucose concentrations ofnormal{+/db)and diabetic(db/db) 
mice treated with T3(0, 100,200,and 500n^gBW) 46 
18. Respiratory quotients(RQ)ofnormal(+/£/&)and diabetic 
mice treated with T3(0, 100,200,and 500 ng/gBW) 47 
XI
 
CHAPTERONE: INTRODUCTION
 
Overview ofDiabetes Mellitus
 
Diabetes mellitus is a major health problem that appears in the written literature dating
 
back approximatelytwothousand years(Kahn and Weir 1994). According to the American
 
Diabetes Association, 16 million people are affected in the United States and an additional
 
500,000 to 700,000 individuals are diagnosed each year. It is the fourth leading cause of
 
death by disease among adults in the U.S. and it is expected that 178,000 individuals per
 
year will die from complications due to diabetes. It is a chronic disease that does not yet
 
have a cure.
 
Diabetes mellitus is a syndrome characterized by high concentrations ofserum glucose
 
(hyperglycemia)due to the inadequate control ofglucose levels. This resultsfrom the lack
 
ofglucose uptake by the skeletal muscle, adipose tissue, and liver, and is also associated
 
with the inability to secrete or appropriately respond to insulin(Kahn and Weir 1994).
 
Because insulin is the normal hormonalsignalfor cellular glucose uptake,an individual who
 
has this syndrome is in a chronic hyperglycemic state. The cause of diabetes is still
 
unknown,however both environmental and genetic factors have been implicated.
 
There aretwo general classifications ofdiabetes mellitus. TypeI diabetes mellitus is
 
insulin-dependent diabetes mellitus(IDDM)and is most widely understood. It is theform
 
of diabetes most prevalent in children (juvenile onset). IDDM individuals are
 
characteristically thin and have extremelylow insulin levels. They produce minute quantities
 
or no insulin due to dysfunctional pancreatic P-cells(the cells which are responsible for
 
insulin production),defects in the insulin gene,and/or defects in the processing ofthe insulin
 
protein(Hadley 1992)which result in low functional levels ofinsulin. Because the lack of
 
insulin prevents glucose uptake by muscle and adipose tissue,these individuals have elevated
 
serum glucose concentrations and elevated ketone body levels due to increased fat
 
catabolism. Excess lipolytic activity occurs in order to provide the necessary energyfrom
 
fat storesin the absence ofglucose uptake(Kahn and Weir 1994). IDDM comprises 10%
 
of all diabetes mellitus cases and is the form ofdiabetes that is most familiar to people.
 
Further discussion ofthisform is not within the scope ofthis project.
 
Typen diabetes mellitus refers to non-insulin-dependent diabetes mellitus(NDDDM)
 
and it isthe mostcommonform ofdiabetes. NIDDM comprises90%ofall diabetes mellitus
 
cases(Kahn and Weir 1994),and it is the subjectofthis study. Itis typically adult-onset,
 
at first asymptomatic,and rather slow in developing. Individuals are characteristically obese
 
and produce excessive insulin, thus they are hyperinsulinemic. However,the tissues in
 
NDDDMindividuals do notrespond to insulin appropriately. Therefore, NIDDM individuals
 
are unableto effectively control glucose uptake because ofinsuhn resistance. NIDDM may
 
be caused by defects in the target cell such as a reduced number ofreceptors on the target
 
tissue surface(DeFronzo etal. 1992), post-receptor defects, altered function in the insulin
 
transduction mechanism due to reduced kinase activity (Stephens and Pilch 1995), or
 
cellular glucose transporter defects. All ofthese can cause hyporesponsiveness to insulin
 
(Hadley 1992)which would contribute to a hj^erglycemic state(DeFronzo et al. 1992;
 
Zorzano etal. 1996). Whereas nearly eighty-five percent ofthose individuals classified as
 
having NIDDM are also obese, the link between diabetes and obesity remains to be
 
determined(DeFronzo etal. 1992). It has been proposed that obesity may be diet-induced
 
(excessive intake ofcalories), may resultfrom decreased energy expenditure,or maybe due
 
to altered lipid metabolism(Guerre-Millo 1996;Beck 1995); However,defective glucose
 
transport seems to be central to the hyperglycemic aspect ofthe syndrome. High serum
 
glucose levels persist since glucose is not properly handled by the insulin-hyporesponsive
 
skeletal muscle and adipose tissue, yet, glucose uptake by the liver continues to take place
 
and this substrate subsequently is converted to and stored as fat. This is also observed in
 
the adipocytes and maylead to obesity because the excess glucose taken up by adipocytes
 
can be converted into fat via lipogenesis and stored as triglycerides. Skeletal muscle from
 
NIDDMindividuals,however,is not able to take Up glucose as readily by other mechanisms
 
therefore the insulin-responsive glucose transport mechanism warrants further investigation.
 
Diabetic Mouse Model
 
In order to study non-insulin-dependent diabetes mellitus, the C57BL/KsJ diabetic
 
{db/db)mouseis employed as the working animal modelfor this syndrome. The diabetes
 
mutation arose spontaneously in the C57BL/KsJ strain and the db gene is autosomal
 
recessive(Hummel et al. 1966; reviewed in Bray and York 1979). As in humans, this
 
mouse model displays high serum glucose concentrations and elevated insulin
 
concentrations, as well as age-dependent development ofobesity(Hummel et al 1966;
 
reviewed in Bray and York 1979). This animal also displays decreased membrane-bound
 
GLUT4 in adipocytes(Gibbs et a/. 1995). Its tissues display insulin resistance and the
 
syndrome is the result ofa genetic defect. The mechanism forNIDDM in the db/db mouse
 
model yetremainsto be determined. Recently,Chuae/a/.(1996)reported that the gene
 
on chromosome 4, which gives rise to the diabetes mutation in the C57BL/KsJ mouse,is
 
also the gerie that codesfor the leptin receptor. The"weight-reducing" hormone,leptin, is
 
said to be the protein product of the oh gene which is secreted by adipose tissue in
 
proportion to the fat content (Pelleymounter et at. 1995; Halaas et at 1995). Leptin
 
treatment in ob/ob mice has been shown to decrease body weight, decrease adiposity,
 
increase metabolic efficiency, and decrease voluntary feeding(Pelleymounter etal. 1995;
 
Halaas etat 1995). However, mice have abnormally high serum leptin levels and
 
whentreated with exogenousleptin do notrespond to treatment(Pelleymounter etat 1995;
 
Halaas etat 1995)thus suggesting a defect in the OB-receptor, also known as the leptin
 
receptor(Chua et al. 1996). The receptor may represent one component ofthe afferent
 
signalling system (leptin action at the brain) but a defect at this level still does not
 
completely explain obesity in this animal model. The efferent signal to the target tissue
 
remains to be identified. This efferent signalling system may play a directive role in
 
specifying targettissue responses or in regulating tissue responsiveness to other hormones.
 
The G57BL/KsJ diabetic(db/db)mouse,a modelforNIDDM and obesity, hasbeen
 
shownto exhibit resistance to thyroid hormone(Tj). Obese-diabetic{dbldb)rmcQ display
 
excess adiposity, high serum T3 cqnceritrations, decreased serum;T4 concentrations(Fehn
 
et at 1988),low metabolic rates(spebific oxygen consumption rates)(Clark 1995), and
 
lower body temperatures(Hummel et at 1966) which suggest that these animals are
 
resistant to thyroid hormone. The animals are therefore considered to be fimctionally
 
"hypothyroid." It has been proposed that, as a result ofbeing T3 resistant, the obese­
diabetic mice accumulatefats dueto decreased energy utilization and decreased mobilization
 
of fat stores (Fehn et al. 1988). Our laboratory has shown that treatment with
 
supraphysiological dosesofT3can overcomethe targettissue resistance leading to enhanced
 
metabolic response, activation of fat mobilization from adipocytes, restored normal
 
metabolic rates,and increased thermogenesis. Thisindicates that the Tj-resistance exhibited
 
by the dh/db animals is not absolute but relatively refractory. Thus,the model allowsfor
 
the study ofT3 effects on physiological events,such as metabolism and glucose uptake.
 
Facilitative Glucose Transporters
 
Obesity is acommon health problem in industrialized societies and it is characterized
 
by increased adipose tissue mass(Guerre-Millo 1996). Obesity may be caused by over
 
eating,lack ofphysical activity, or maybe genetically determined. It is attributed to energy
 
imbalance, meaning that more calories are taken in asfood than are expended to maintain
 
the basal metabolic rate or to engage in physical activity. In humans, obesity is strongly
 
associated with the development ofNIDDM(Considine etal. 1995),and was believed to
 
be caused by defects in the oh gene (Pelleymounter et al. 1995; Halaas et al. 1995).
 
However,recent studies havefound no mutations in either the oh gene or the oh receptor
 
genein humans,thusthey are notthe cause ofobesity(Considine etal. 1996). Alternative
 
explanations are required to explain this pathology,and mayinclude a defect in the glucose
 
transporter or in the vesicular translocation/trafficking mechanism. Although this defect
 
would not explain the entire basisfor obesity,it might explain the redistribution ofglucose
 
awayfromthe muscleto liver and adiposetissues. Since the skeletal muscle cannot take up
 
glucose efficiently inMDDMindividuals, high serum glucose levels prevail which result in
 
glucose uptakethat predominantly occurs within the liver and adipose tissue. Glucose can
 
betaken up in adipose tissue by wayofglucose transporters that are expressed independent
 
ofinsulin action and inthe liver via the GLUT2transporter(which will be discussed later).
 
Excess glucose taken up by these cells would then be converted into fats which would
 
contribute to increased adiposity.
 
Six proteins have been identified as being responsible for the facilitated diffusive
 
transport ofglucosedown its concentration gradient across cell membranes and these have
 
been designated as facilitative glucose transporters: GLUTl,GLUT2,GLUT3,GLUT4,
 
GLUTS(Pessin and Bell 1992;Mueckler 1994), and GLUT?(Mueckler 1994), whereas
 
GLUT6(Stephens and Pilch 1995)has been identified as a pseudogene with no specific
 
function. Thistransport is driven exclusively bythe chemical gradient and notthe hydrolysis
 
ofATP, nor is it coupled to either sodium or proton gradients.
 
GLUTl is expressed in the brain,kidney,colon,and red blood cells and is responsible
 
for basal glucose uptake. This transporter is constituitively expressed and has aKm value
 
ofapproximately 6.9 mM. This meansthat it hasa high affinity for glucOse but it saturates
 
at physiological glucose concentrations. It is responsible for basal glucose transport and it
 
plays an important role in glucose transport across the blood brain barrier as well as other
 
barrier tissues(Mueckler 1994;Livingstone etal. 1996). GLUT2,a protein predominantly
 
expressed in the liver,is involved in hepatic uptake and release ofglucose and it apparently
 
functioiis as part of a glucose sensor. This transporter has a high Km for glucose
 
(approximately 13,2 mM),hasalow affinity, and is not saturated vdthin normal physiologic
 
glucose conceritrations (Livingstone et til. 1996), Therefore^ it transports glucose in
 
quantities directly proportional to serum glucose concentrations. GLUTS is widely
 
distributed in human tissues(Mueckler1994)but is predominantly expressed iii the brain
 
and is responsiblefor constitutive neuronal glucoseuptake(Pessin and Bell 1992). GLUTS,
 
unlike the other transporters, has a verylowKm for glucose(1.8 mM)and a high affinity
 
for glucose(Mueckler 1994)but it saturates atlow glucose levels; Thistransporter serves
 
as a fail-safe mechanism for glucose transport across the blood-brain-barrier in order to
 
ensure thatthe brain is constantly supplied with glucose,even during hypoglycemic states.
 
TheGLUT4glucose transporter is an insulin-regulatable glucose transporter that isfound
 
in adipose tissue, cardiac muscle,and skeletal muscle. This transporter will be discussed in
 
more detail below. GLUTS is expressed in the jejunum.It has been characterized as being
 
responsibleforintestinal absorption offructose and possibly other hexoses(Pessin and Bell
 
1992; Mueckler 1994). GLUT6 has been identified as a pseudogene having no specific
 
target tissue or function(Stephens and Pilch 1995). GLUT? transporter is expressed in
 
intracellular membranes of hepatocytes and possibly other gluconeogenic tissues. This
 
transporter allows glucose to diffuse freely from the endoplasmic reticulum of
 
gluconeogenic tissues in response to the action ofglucose-6-phosphatase on glucose-6­
phosphate(Mueckler 1994;Stephens and Pilch 1995). However,the actual significance of
 
this transporter's function remains unclear. The six different glucose transporter isoforms
 
have distinct characteristics and fiinctionsthat are dependent on the tissue in which they are
 
expressed. As such,the glucose transport rates ofthese glucose transporter isoforms are
 
characteristic ofthefunction ofthe target tissue.
 
The GLUT4 glucose transporter protein, the focus ofthis project, is expressed in
 
skeletalmuscle,cardiac muscle^ and adipose tissue. It has aKm value ofapproximately 4.6
 
mM, it is positively responsive to insulin, and is involved in insulin-stimulated glucose
 
uptake(Pessin and Bell 1992,Stephens and Pilch 1995). This transporter is responsible for
 
a rapid increase in glucose uptake in response to increased serum insulin concentrations
 
(Mueckler 1994; Stephens and Pilch 1995). When stimulated by insulin, GLUT4
 
concentrations in the plasma membrane ofcells normally increase approximately 20-fold
 
(Pessin and Bell 1992). It has been reported that the plasma membrane GLUT4fraction in
 
adipose tissue(Stephens andPUch 1995)and skeletal muscle(Zorzano etal 1996)ofobese
 
NIDDM patients is reduced. This would have an overall impact on glycemic regulation
 
since glucose cannot be readily taken up by the target tissues. Thus, it would be of
 
importance to gain a better understanding ofthe GLUT4 regulatory mechanisms and
 
expression inNIDDM. SinceNIDDMindividuals haveimpaired glucose uptake, alterations
 
in the structure,function,or regulation ofthe glucose transporters, specifically GLUT4,are
 
good candidate mechanisms for transport defects associated with this syndrome. The
 
GLUT4glucose transporter is an integral membrane componentfound in insulin responsive
 
tissues. Little is known ofthe regulatory mechanisms which control GLUT4transporter
 
expression and distribution in the skeletal muscle and adipose tissue. This will be the central
 
focus ofthe study.
 
GLUT4 Vesicular Trafficking
 
The GLUT4 transporter facilitates glucose uptake across the plasma membrane
 
between the serum and cell cytoplasm and normally increases in number with increased
 
insulin concentrations. The GLUT4transporter protein is processed and translocated like
 
other proteins within the cell by the following mechanisms. Proteins are synthesized at the
 
endoplasmic reticulum and move toward the Golgi complex for fiarther processing and
 
modification within a spike-coated vesicle as part ofa processknown as vesicular trafficking
 
(Morris and Frizzell 1994; Gauter et al. 1994). The vesicle fuses with the c/5-face ofthe
 
Golgicomplex,and subsequently buds fi-om the organelle. The vesicle then fuses with the
 
medial-incG ofthe Golgi complex and after further modification and processing,the vesicle
 
buds. The budded vesicle then approaches and fuses with the trans-iaco. ofthe Golgi
 
complex. Withinthe trcms4acQ ofthe Golgi complex,the vesicle is labelled with mannose­
6-phosphate receptors and these identify the vesicle as one which will reside in the
 
cytoplasm. The vesicle is removed from the secretory pathway and is localized in a region
 
of the Golgi complex where the vesicle becomes clathrin-coated. Such processing is
 
characteristic oflysosomal vesicles. However,ifthe vesicle is to be secreted, it remains
 
uncoated, as is the case with GLUT4-containing vesicles (Stephens and Pilch 1995).
 
Subsequently,these vesicles with their protein contents are then transported towards the
 
plasma membrane(translocation) where the vesicles will dock and fuse with the plasma
 
membrane and incorporate their contents into the membrane as integral transmettibrane
 
proteins(Appendix 1).
 
Vesicles are believed to betransported through the cytoplasm driven by kinesin along
 
microtubules(Morris and Frizzell 1994). A vesicle attaches to kinesin, a molecule that
 
serves asthe motorinthe translocation process,and this molecule is activated by Ca^^. The
 
intracellular activity ofkinesin is regulated by the influx ofCa^^ into the cell or Ca^^ release
 
from the endoplasmic reticulum(or the sarcoplasmic reticulum ifthe process is occurring
 
within the skeletal muscle). This propOrtedly stimulates movement of kinesin along a
 
microtubule,which transports the vesicle towardsthe surface ofthe cell(Morris and Frizzell
 
1994). The vesicle then comesin contact with various docking proteins at the membrane
 
surface. These proteins enable the vesicle to dock and fuse thereby integrating into the
 
membrane the vesicular protein components(Appendix 2).
 
Vesicular translocation, docking, and fusion with the plasma membrane involve a
 
series of steps regulated by several key proteins. The vesicle membrane contains the
 
proteins synaptobrevin and synaptotagmin(12kDaand 65 kDa integral membrane proteins,
 
respectively). These form a 7S docking complex with a 25 kDa protein SNAP-25
 
(Synaptosomal Associated Protein-25), and syntaxin(32kDa),both ofwhich are located
 
in the plasma membrane ofthe cell(Scheller 1995;Bark and Wilson 1994). As a-snap
 
(Soluble NSF Associated Protein) associates with the 7S complex synaptotagmin is
 
dislodged. A 20S complex isformed when cytoplasmic NSF(N-ethylmaleimide-Sensitive
 
Factor)associates with a-snap onthe7S complex. NSF protein binds ATP and, as a result
 
ofATP hydrolysis,NSF and a-stiap dissociate from the 20S complex. Syntaxin, which is
 
tightly associated withthe integral membrane proteins Neurexins and Ca^^ channel proteins,
 
isthus exposed and is able to associate with synaptotagmin on the vesicle. The association
 
stimulates a conformational shift of the associated complex causing an influx of Ca^^.
 
Synaptotagmin,which is sensitive to Ca^^ binds and this causes another conformational
 
shift in the associated proteins. This shift subsequently causes SNAP-25 and the syntaxin­
10
 
synaptotagminfijsion complexto separate along the cell membrane thereby creating a"gap"
 
in the cell membrane which enables the proteins from the vesicle to become embedded
 
within the membrane(Bark and Wilson 1994; Scheller 1995). Stephens and Pilch(1995)
 
state that the docking-fusion mechanism ofGLUT4-containing vesicles is similar to that of
 
the neurotransmitter secretion model(as described above), differing only in afew docking
 
proteinsthat are specific for GLUT4. Although the GLUT4translocation mechanism may
 
be a point for potential defects within NIDDM,non-functional docking proteins on the
 
vesicle or plasma membrane as well as lack offusion and integration ofvesicular contents
 
are also potential candidates. The current study will address translocation and docking of
 
the GLUT4glucose transporters in tissues from normal and obese-NIDDM subjects.
 
GLUT4 Studies
 
Studiesin transgenic mice,into whichthe fiinctional GLUT4gene has been transfected
 
from humans,and diabetic animal models have consistently shown that insulin increases the
 
quantity ofGLUT4 at the plasma membrane ofadipose tissue and leads to a concomitant
 
decrease in cytoplasmic GLUT4 quantity. Zorzano et al. (1996)reported that insulin
 
treatment similarly caused the GLUT4 quantity in adipose tissue and skeletal muscle to
 
increase at the plasma membrane and decrease in the cytoplasm. Other studies using
 
transgenic animals showed that tissues from transgenic animals (skeletal muscle and/or
 
adipose tissue) had significantly greater GLUT4 present in the plasma membrane in
 
comparisonto their non-transgenic counterparts(Brozinick etal. 1996; Gibbs etal. 1995;
 
Olson and Pessin 1995; and Hansen et al. 1995). Upon insulin stimulation, there was a
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more dramatic increase in membrane bound GLUT4transporter quantity in the transgenic
 
mice in comparison to non-transgenic mice. There was a concomitant decrease in the
 
GLUT4quantity in the cytoplasm indicating that GLUT4-containing vesicles translocated
 
from the cytoplasm to the plasma membrane. Gibbs etal.(1995)utilized a hGLUT4db/dh
 
transgenic mouse that carries a functional human GLUT4 gene which leads to GLUT4
 
transporter overexpression. This study showed that the glucose transport defect(reduced
 
plasma membraneGLUT4content)in transgenicdb/db mice could be compensated for by
 
inducing extra GLUT4transporters which correctfor insulin resistance. This indicated that
 
insulin insensitivity in this model ma^y be at the level ofvesicular translocation, doclting, or
 
fusion,since upregulation oftranspofter expression could overcome the glucose transport
 
defect. The transgenic db/db mice showed a marked decrease in hyperglycemia due to
 
increased glucose transport via the GLUT4glucose transporter in Comparison to the non­
transgenic mice. Thetargettissues, skeletal muscle and adipose tissue,in these mice
 
are resistantto insulin's action on GLUT4induction and/ortranslocation which suggests that
 
GLUT4 translocation may be regulated by another factor or another hormone since
 
translocation took place in the absence ofinsulin signalling. The translocation defect can
 
be compensated by GLUT4 overexpression but it can also be potentially corrected by the
 
direct action ofanother hormone otherthan insulin on elements involved in the translocation
 
process. Ifthis is the case, an increased number ofGLUT4 transporters at the plasma
 
membrane could facilitate increased glucose uptake and could improve the glycemic status
 
oftheMDDM subjects. Sincethe process ofGLUT4transporter protein expression in the
 
plasma membrane and translocation is insulin-responsive, the regulation ofthe GLUT4
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transporter is a likely candidate for altered function in non-insulin-dependent diabetes
 
mellitus and warrants further investigation.
 
NIDDM and Obesity
 
Several factors that may contribute to the onset of obesity include overeating,
 
metabolic defects,hypothalamic disorders,increases in carbohydrate,fat, or protein intake,
 
and decreased physical activity(Beck 1995; Guerre-Millo 1996). Adiposity can manifest
 
in general categories ofpresentation which reflect either cellular hypertrophy or hyperplasia,
 
or both. Enlargement ofthe adipocytes may be due to an increase in cell volume which is
 
associated with excessivefat storage and is characteristic ofhypertrophy. Alternatively,an
 
increase in the overall number ofadipocytes is characteristic ofhyperplasia which results
 
from excessive mitotic divisions(Hadley 1992). Adipocytes within adipose tissue serve as
 
an efficient energy repository by housing fat droplets which contain two times the amount
 
of potential energy per unit of weight compared to either proteins or carbohydrates.
 
However, the prevalence of obesity in relationship to non-insulin-dependent diabetes
 
mellitus is not yet understood.
 
Eighty-five percent of individuals with NIDDM are also characteristically obese.
 
Studies have reported increased adipocyte volumes and decreased membrane-bound GLUT4
 
in adipocytes ofNIDDM subjects (Fabres-Machado and Saito 1995) and oht^Q-db/dh
 
animals (Estrada unpublished observations). The adipocytes in subjects with NIDDM
 
generally increase in lipid content, cell number, and/or cell size(Bjomtorp 1987), thus
 
accounting for the obesity associated with the syndrome. Obesity is also associated with
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insulin resistance such that insulin-sensitive tissues(primarily skeletal muscle and adipose
 
tissue) are not able to respond to insulin appropriately and thus have impaired glucose
 
uptake. Since the majority ofNIDDM individuals are obese; perhaps obesity is also
 
associated with alterationsinfacilitated glucose transport via defective GLUT4transporter
 
function. Onset ofobesity in NIDDM subjects, including the db/db mowse,is associated
 
with decreasesin both specific Ojconsumption,as well as total metabolic rate(Glark 1995;
 
Jequier 1987). These responses are also observed in a phenotypically-related model,the
 
mouse(Boissonneault etal. 1978;Oh and Kaplan 1994). The reduced metabolism
 
ofNIDDM subjects apparently conserves energy, which is then stored causing increased
 
adiposity. The mechanism that results in a decreased metabolic rate and increased adiposity
 
(pofentiallyleading to the onset ofNIDDM)however, still reniains undetermined.
 
Glucoregulatorv and Thyroid Hormones
 
Thereare many hormonalsignalsthat areinvolved in regulating glycemic status,such
 
as glucagon,insulin,and the catecholamines(specifically epinephrine). Glucagon stimulates
 
the release ofglucose fi'om the liver via glycogenolysis(in order to maintain short-term
 
levels of blood glucOse in a well-fed animal) or gluconeogqnesis (in order to maintain
 
glucose levels under prolonged fasting or exercise periods). Insulin is secreted by the Islets
 
ofLangerhansinthe pancreas,specifically the P-cells,in response to elevated serum glucose
 
levels. Insulin enhances glucose uptake bythe hepatocytes,myocytes,and adipocytes where
 
it is metabolized, stored as glycogen, or used as a substrate to synthesize proteins or fats.
 
Epinephrine,however,inhibits glucose uptake by adipocytes during periods ofstress. This
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ensures that dtiring times ofsuch activity, glucose is taken up niore readily by the liver,
 
skeletal muscle,or brain instead ofbeing stored away. Thus,serum glucose levels are not
 
regulated solely by one hormone but rather regulation involves the action of multiple
 
hormonesthat are dependent on the physiological status ofthe individual.
 
While a variety ofcausative agents(mentioned above)have been proposed in the
 
regulation ofthe glycemic status within an individual, another hormone,triiodothyronine
 
(T3),maybeindirectly involved in regulating the glucose levels. Thyroid hormone plays a
 
role in the regulation ofgrowth,development,and metabolism(Glass and Holloway 1990).
 
Thyroid hormone controls the baseline metabolic rate ofanimals and is also permissive to
 
the action of other hormones such as insulin (Hadley 1992). This means that thyroid
 
hormone action is required for insulin to act on the insulin-sensitive tissues and ehcit a
 
response. However,NIDDM individuals are resistant to insulin and their tissues cannot
 
adequately take up glucose. Thus,thyroid hormone's permissive action to insulin should
 
increase insulin sensitivity atthe targettissues and thyroid hormone should be accounted for
 
as a potential mediator in NIDDM.
 
Thyroid hormone is regulated at several levels and by several tissues. The
 
hypothalamusregulates pituitary gland secretion ofthyroid stimulation hormone(TSH)via
 
thyrotropin releasing-hormone(TRH). The pituitary gland produces and releases Thyroid-

Stimulating Hormone(TSH) which, in turn, stimulates the thyroid gland to produce
 
thyroxine(T4),the metabolically inactive form ofthyroid hormone. T4is converted to the
 
metabolically active triiodothyronine(T3)via 5'-monodeiodinase in the liver and kidney. T3
 
is responsible for regulating metabolic activity within most cells(Oppenheimer 1994). It
 
acts by binding to nuclear receptors located On theDNA where it forms dimeric hormone-

receptor complexes which are responsible for regulating gene transcription and the
 
expression ofgene products. This hormone is responsible for regulating metabolism at the
 
tissue level. It potentiates lipogenesis(fat synthesis)in the liver by inducing the synthesis
 
ofhepatic lipogenic enzymes, lipolysis (fat catabolism)in adipose tissue by inducing the
 
lipolytic enzymes (Glass and Holloway 1990), and thermogenesis(heat production) in
 
skeletal muscle by inducing Na^/K^-ATPase (Glass and Holloway 1990; Oppenheimer
 
1994). It is, therefore, an important regulator ofoverall energy balance.
 
The db/db mice are resistant to thyroid hormone(T3)which means that the target
 
tissues are relatively unresponsive to the action ofthyroid hormone. While these animals
 
have high serum T3levels which makethem technically hyperthyroid,they are functionally
 
hypothyroid since they are hyporesponsive to T3. The target tissue resistance can be
 
overcome with supraphysiological doses which results in an enhanced metabolic response,
 
activation offat mobilization from adipocytes, restoration to normal metabolic rates, and
 
increased thermogenesis(Clark 1995;Estrada unpublished results). These are responses
 
that are potentially linked to glucose transport since an increase in glucose uptake can
 
provide the substrate to be utilized in metabolic and thermogenic processes. Since db/db
 
animals are T3resistant,thyroid hormone cannot elicit its permissive action to insulin within
 
the animal's tissues. This may contribute to the insulin resistance characteristically seen in
 
NIDDM subjects. Thus,the insulin-responsive GLUT4transporter is a likely candidate for
 
thyroid hormone regulation.
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Thyroid hormone has been reported to regulate GLUT4expression in adipose tissue
 
(Matthei et al. 1995)and skeletal muscle(Weinstein et al. 1994; Weinstein et al. 1991;
 
Casla et al. 1990). A pilot study (Estrada unpublished results) on the effect of T3 on
 
GLUT4 expression has also shown that T3 regulates the GLUT4transporter in the db/db
 
mouse. Thyroid hormone treatment regulates the redistribution (translocation) ofthe
 
GLUT4-containing vesicles within the cjhoplasm of adipocytes towards the plasma
 
membrane and may regulate the docking-fusion mechanism(Estrada unpublished results).
 
However, no pubhshed information exists on the role of thyroid hormone on GLUT4
 
glucose transporter regulation in mice.
 
Proposed Effect ofThyroid Hormone on GLUT4expression
 
In the present study,the effect ofT3on GLUT4glucose transporter expression will
 
be assessed in lean C57BL/KsJ +/db and obese-diabetic C57BL/KsJ db/db mice. This will
 
be done by comparing the content ofGLUT4transporters in adipose tissue and skeletal
 
muscle from vehicle-treated normal and obese-diabetic mice with the tissues obtained from
 
normaland diabetic mice treated with exogenous T3for nine days. Because adipose tissue
 
and skeletal musclein db/db mice are resistant to insulin(reviewed in Bray and York 1979;
 
Hummeletal. 1966),the quantity ofGLUT4 presentin the plasma membrane is expected
 
to be below normal since insulin action is needed to induce GLUT4 mRNA expression
 
(Sinha etal. 1991). The quantity ofGLUT4in the cytoplasmic fraction(the result ofgene
 
transcription and translation)and plasma membrane fraction(the result ofprotein transport,
 
docking,and fusion)wall be evaluated.
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The target tissues in individuals with NIDDM are resistant to insulin leading to
 
impaired glucose uptake and hyperglycemia. In insulin- and Tj-resistant dh/dh mice,the
 
insulin response may be restored via overcoming the thyroid hormone resistance with
 
supraphysiological doses of Tj. This could then result in regulation of the GLUT4
 
transporter via Tjtreatment. Under the assumption that T3 may play a role in GLUT4
 
expression and/or vesicular trafficking, treatment with thyroid hormone should increase
 
GLUT4 transcription. This, in turn, should lead to increased translation ofthe GLUT4
 
transporter protein. Subsequently, an increase in GLUT4-containing vesicles should be
 
observed,as well as increased vesicle fusion with the plasma membrane ofadipocytes and
 
myocytes ofdb/db mice.
 
There are five potential sites of action for regulation of the GLUT4 glucose
 
transporter ifthe GLUT4 quantity at the plasma membrane increases in response to T3
 
treatment. 1)T3 may regulate gene expression at the transcriptional level because thyroid
 
hormone has nuclear receptors on the DNA. This could potentially regulate gene
 
transcription ofmRNA for the GLUT4 transporter or various elements involved in the
 
GLUT4trafficking mechanism;2)This event could alternatively lead to increased translation
 
ofthe GLUT4transporter protein by enhancing translational efficiency;3)or by stabilizing
 
the GLUT4transporter mRNA;4)Triiodothyronine might also increase incorporation of
 
GLUT4transporters into vesicles via regulation ofprocessing occurring within the Golgi
 
complex; 5) Thyroid hormones (T^ in this case) have been shown to regulate actin
 
polymerization and this may play a role in GLUT4 vesicle transport and fusion with the
 
plasma membrane(Leonard 1997). An assessment oftotal GLUT4 protein expression and
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cellular distribution was performed in a pilot project to narrow these possibilities.
 
The pilot project of GLUT4 expression in adipocytes was conducted using an
 
experimental design similar to that proposed for this study except that the tissues were not
 
homogenized fresh but rather after storage at -20°C. Normal{+/db)and diabetic(db/db)
 
mice were treated with exogenous Tj(0 ng/gBW or 500 ng/gBW)for ten days and each
 
treatmentgroup consisted offive animals. Animals were euthanized on day 10 ofstudy with
 
CO2. Adipose tissue was extracted and homogenized in order to separate the cytoplasmic
 
and plasma membrane fractions. Homogenates(0.5 pg protein/100 pi)were loaded onto
 
nitrocellulose paper using a dot blot apparatus for immunodetection of the GLUT4
 
transporter. A commercial polyClOnal GLUT4 antibody (rabbit-anti-insulin regulatable
 
glucose transporter,East Acres Biologicals)was used to identify the GLUT4transporter
 
and was visualized using chemilumenescence detection(AmershamRPN 2108). GLUT4
 
transporters were quantified using a Bio-Rad video densitomter and data were reported as
 
OD units.
 
TotalGLUT4expression in +/db mice increa.sed with T3treatment which suggested
 
GLUT4induction in responseto T3. Jndb/db tmce,total GLUT4expression decreased with
 
T3 treatment(Table 1). The quantity ofGLUT4in the cjdoplasm of+/db mice increased
 
with T3 treatment (0.158±0.07 vs 0.196±0.05, repectively; p<0.05) whereas in db/db
 
animals,the cytoplasmic quantity decreased in response to T3(0.284±0.04 vs. 0.178±0.07,
 
respectively; p<005). The quantity of membrane-bound GLUT4 transporter in +/db
 
animals did notchange with T3treatment(0il68±0.05 vs.0.170±0.02,respectively; p>0.05)
 
which suggested Tj had no eflfect and represented^ normal turnover. However,in db/db
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TABLE 1. OD readings ofadipocyte cytoplasmic and membrane-bound GLUT4 proteins
 
in vehicle-treated(0ng Tj/gB\\0and Tj-treated(500ng/gBW)normal(+/db)and diabetic
 
mice. (ValuesiSEM,n=5).
 
Phenotype/Treatment Group Cytoplasm Membrane-Bound TotalGLUT4
 
+/0 0.158±0.068 0.168 ±0.053 0.326±0.16
 
db/G 0.284±0.040 0.062±0.058 0.346±0.13
 
+/500 0.196±0.047 0.170±0.020 0.366±0.23
 
db/500 0.178 ±0.071 0.090±0.024 0.268±0.12
 
animals,the GLUT4 quantity increased at the plasma membrane with T3 as a concomitant
 
decrease in cytoplasmic GLUT4 was observed. These were indications that GLUT4
 
transporters were being redistributed from the cytoplasm to the plasma membrane in db/db
 
animals Theintent ofthe pilot study wasto determine ifthyroid hormone altered GLUT4
 
transporter expression in db/db mice. Based on this study, it was concluded that thyroid
 
hormone was not likely to be affecting GLUT4 transporter mRNA transcription in the
 
insulin-resistant db/db mice because a pool ofcytoplasmic GLUT4transporters existed in
 
vehicle-treated mice.
 
Adipocjdes were evaluated in the pilot study as a reference point so as to provide a
 
framework on the role ofthyroid hormone in regulating GLUT4 expression. This could
 
then be used to formulate hypotheses in reference to the action pfthyroid hormone on
 
GLUT4 expression in another insulin responsive tissue, skeletal muscle,and the impact it
 
would have on metabolic responses observed in other studies. In the current study,GLUT4
 
protein expression and subcellular distributions will be assessed in normal and diabeticmice
 
to see ifT3 influences GLUT4 transporter trafficking phenomena. This will be done by
 
quantifying the total GLUT4transporter presentin the cell cytoplasm and plasma membrane
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under variousthyroid hormonetreatmentsto determine ifGLUT4transporter translocation
 
from the cytoplasm to the plashia membrane occurs. The total GLUT4 quantity will be
 
indicative ofthe induction process and the distribution ofthe cytoplasmic and membrane-

bound GLUT4 fractions will be representative of the trafficking mechanism. The
 
implication ofincreased numbers ofmembrane-bound GLUT4transporters is that it would
 
allow for increased glucose transport into skeletal muscle and adipose tissue. This would
 
then be utilized by the skeletal muscle as a fuel source for thermogenesis. Ifan increase in
 
heat production does occur,the body temperatures oidb/db mice should increase and an
 
increase in oxygen consumption should be observed.
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CHAPTERTWO: MATERIALSAND METHODS
 
Animals and Tissues
 
C57BL/KsJ heterozygous normal(+/db)and homozygous diabetic(dbldb)mice were
 
obtained from Jackson Laboratories(Bar Harbor, Maine). The animals were housed at
 
approximately23°C under a 14:10 light;dark cycle. Lights were on from6am until8 pm
 
daily, and five animals were housed per cage in 11"long X7" wideX 5" tall plastic cages
 
with wood chip bedding and white tissue. Water and Teklab 4% rodent chow were
 
available adlibitum.
 
Female +/db zxA dbldb mice,8-10 week old, were preconditioned 1 week prior to
 
study by handhng, exposure to metabolic chambers, and being subjected to temperature
 
reading procedures. After preconditioning, animals received daily intraperitoneal injections
 
ofthyroid hormone(L-3,5,3'triiodothyronine; Sigma#T2877)in doses of0, 100,200,and
 
500ng Tj/g body weight for nine consecutive days(Kalousek 1986;Clark 1995). T3 was
 
prepared daily using 100 pg/mlin 0.5 mMNaOHand was protected from light via wrapping
 
the injection bottle with aluminum foil. The control animals received intraperitoneal
 
injections of0.5 mMNaOHin proportional volumes(2 gl/g body weight). Each treatment
 
group consisted of five +/<i& and fivedbidb animals. Injections were administered between
 
8am and 10am after daily body weights, metabolic readings,and bodytemperatures were
 
recorded. On day 10, animals were euthanized by COj. Blood was collected from each
 
animalby cardiac puncture. Tissues(adipose tissue and skeletal muscle)were excised and
 
processed(see below)to obtain homogenatesfor GLUT4 analysis.
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Metabolic Rate Determinations and Temperature Studies
 
Oxygen consumption and carbon dioxide production rates ofthe mice were measured
 
for 3 minutes each day for 10 days using an Ametek S-3A/n Oxygen Analyzer and an
 
Ametek CD-3A Carbon Dioxide Analyzer. An open flow system using room air was
 
utilized and wascalibrated daily priorto use with gases ofknown concentrations. Readings
 
were taken at a constant flow rate of400 ml per minute (as determined by Gilmont
 
Flowmeter,modelD-665)in order to determine relative metabolic responses. Daily rectal
 
bodytemperatures for normal and diabetic mice were recorded using a temperature probe
 
(Sensortek Thermocouple, modelBAT-12)and radiant heat was measured on days 7-10
 
with a Microprocessor Thermometer(Type J-K-T Thermocouple,modelHH21). Data are
 
reported as respiratory quotient(RQ,mlCOJ ml Oj)and temperature("C).
 
GLUT4Fractionation Studies
 
Omental adipose tissue (0.25 g)and gastrocnemius skeletal muscle(0.05 g)were
 
excised and homogenized in 1 ml ofSTM/PMSF buffer(0.32M sucrose,3mM MgCl2,and
 
0.5% Tween20,0.IMPhenylmethylsulfonylFluoride)using a motorized glass homogenizer
 
at room temperature for 45 seconds. Homogenates were centrifuged at 14,000 g for 5
 
minutes at4°C(Herman etal. 1994)to produce a supernatant containing the cytoplasmic
 
vesicles and a pellet containing the plasma membrane with docked vesicles. The supernatant
 
(approximately 1 ml)wastransferred to afresh microcentrifuge tube. In order to splubilize
 
membrane-bound proteins in the pellet(docked vesicles and fused transporters), 5 ml of
 
STM buffer wasadded to the pellet and this wassubsequently sonicated(Bronwill Biosonik
 
23
 
model)for 1 minute at80% power and the resultant homogenate centrifuged at 14,000 g
 
for5 minutes at4°C(Herman a/. 1994)to remove remnantsofthe plasma membrane and
 
vesicles. The homogenates were stored at -20°C until analyzed.
 
GLUT4 Quantification
 
The Coomassie Brilliant blue method(Bradford 1976;Matthaei etal. 1995)using a
 
Bovine Serum Albumin(BSA,Sigma#A7906)standard was utilized to quantify the protein
 
content ofthe supernatants and the pellets.
 
A 100 pi aliquot of homogenate (approximately 0.313 pg)was subjected to dot
 
blotting and immunodetection using a polyclonal antibody against GLUT4(Rabbit Anti-

Insulin Regulatable Glucose Transporter,East Acres Biologicals)(Burcelin 1993). A 96­
well microtiter plate was prepared that contained various dilutions ofthe supernatant and
 
pellet samples resulting in 0.313 pg total protein/100 pifor dot blot procedures. A 100 pi
 
aliquot ofeach sample wasloaded into individual wells ofthe dot blot manifold. Samples
 
were loaded on to the nitrocellulose membrane(0.2 pm,Protran#BA83)by vacuum and
 
each well was rinsed twice with 100 pi TBS(20 mM Tris, 500 mM NaCl,and 0.0001%
 
merthiolate,pH 7.5). The nitrocellulose paper was blocked withBLOTTO(5% Carnation
 
non-fat milk in TBS, Tris-buffered Saline) for 30 minutes at room temperature, while
 
shaking. A 1:10,000 dilution ofGLUT4 polyclonal antibody(5 pi in 50 mlBLOTTO)was
 
added to the blot which was inCubated in a covered polyethylene dish while shaking
 
overnight atroom temperature. This wasfollowed with 3BLOTTO rinses for 10 minutes
 
each at room temperature. After the third rinse, 10 pi of the secondary antibody
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(biotinylated goat-anti-rabbitIgG,Signia#B-9642)in 25 mlBLOTTO(a 1:2500 dilution)
 
was added and incubated at room temperature for 3 hours while shaking. Following this
 
incubation, blots were rinsed in TBS 3 times at room temperature for 10 minutes each.
 
Twenty microliters ofavidin-horse radish peroxidase(AV-HRP,Bio-Rad)in 20 ml TBS(a
 
1:10,000 dilution)wasadded and incubated at room temperaturefor 1 hour while shaking,
 
followed by3rinses in TBS. The blot wasthen subjected to chemiluminescence detection
 
(Amersham #RPN2108)using Kodak RP X-Omat fihn. The GLUT4 fluorograms were
 
quantified using aBio-Rad model620 video densitometer(Herman etal. 1994). GLUT4
 
protein data are reported as Optical Density(O.D.)uruts.
 
Serum Glucose Determination
 
Serum glucose concentrations were determined with a commercial glucose assay kit
 
(Sigma#115A)using 0.4 pi ofserum fi^ omeach animal. This assay producesa colorimetric
 
response measured at520nm using a microplate reader(BIO-TEK instruments. ModelEL
 
312e)that is proportionalto the serum glucose concentrations. Data are reported as mg/dL.
 
Statistical Analysis
 
Data represeneting body mass,temperature, metabolic studies, GLUT4transporter
 
protein characterization, and the serum glucose assay were subjected to multifactorial
 
analysis ofvariance(ANOVA)and Duncan's Multiple Range Test(Mason et al. 1989).
 
Data are reported as means± SEM and n=5 in all cases. A single asterisk(*)denotes
 
significance at p<0.05and two asterisks(**)denqte significance at p<0.01.
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 CHAPTERTHREE: RESULTS
 
GLUT4Fractionation Characterization
 
The effect of T3 on GLUT4 transporter expression in +/db and db/db mice was
 
investigated by comparirig the totaiGLUT4transporter expression, cellular distribution of
 
and the fraction ofGLUT4tr^portersassociated with the plasnia membrane in adipocytes
 
-treated animals. Tissue homegenates
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Figure 1. Total GLUT4transporter Content in adipocytes ofnormal(+/<®)and diabetic
 
(db/db)mice treated with T3(0,100,200,and 500 rig/g BW). Comparisons are between
 
phenotypes at thegiyen dose(Values are±Sem,n=5).
 
mice in responseto T3(Figure 1).
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Thetotal GLUT4quantity in adipocytes of+/db animalsthat were vehicle-treated or treated
 
withTOO or200 ng Tg/gBW were not altered. In the mice that received 500 ng Tj/gBW
 
dose, the total GLUT4 quantity decreased in comparison to the vehicle-treated animals
 
(1.758±0.15 vs. 1.99±0.19OD units,respectively; p<0.01). These data suggest that within
 
physiological concentrations T3 treatment does not alter the number ofGLUT4 glucose
 
transporters and apparently does not regulate induction. In dh/db mice,the total GLUT4
 
quantity in adipocytes ofvehicle-treated animals was approximately50%less than normal,
 
vehicle-treated animals (0.886±0.15 vs. 1.99±0.19 OD units, respectively; p<0.01).
 
However,increasing doses ofT3 increased total GLUT4transporter expression in db/db
 
mice(Figure 1)with maximal expression occurring at 500 ng T3/gBW. Atthis dose,the
 
total quantity of GLUT4 transporters was greater than vehicle-treated db/db mice
 
(1.928±0.11 vs. 0.886±0.15 OD units, respectively; p<0.01)and approached the quantity
 
observed in vehicle-treated, +/db animals(1.92840.11 vs. 1.99±0.19OD units, respectively;
 
p>0.01). This suggests that GLUT4 transporter induction occurred in response to T3­
treatment which resulted in normalization oftotal GLUT4transporter quantities.
 
The quantity ofGLUT4transporters in the cytoplasm ofadipocytes was assessed in
 
+/db and db/db mice(Figure 2). The baseline expression ofGLUT4transporter protein in
 
the cytoplasm ofadipocytes ofvehicle-treated, +/db animals was 1.488=1=0.18 OD units and
 
no change was observed at 100 and 200 ng T3/gBW doses. Treatment with 500 ng T3/g
 
BW, however, caused a decrease in quantity (1.488=1=0.18 vs. 1.04=1=0.13 OD units,
 
respectively; p<0.01). The basehne quantity of cytoplasmic GLUT4 transporters in
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Figure 2. Gytbplasmie GLUT4 transporter content in adipocytes of nbrinal (+4/5) and 
diabetic {db/db) mice treated with T, (0, 100, 200, and 500 ng/g BW). Comparisons are 
between phenotypes at the given dose (Values are ± SEM, n-5). 
adipocytes ofdb/db mice was approximately 50% less than normal, vehicle-treated animals 
(0.624±0.11 vs. 1.488±0.18 OD units, respectively; p<0.01). In diabetic mice, the 
^0. 
dose of 200 ng Tj/g BW (0.288+0.10 OD units; p<0.05) in comparison to the vehicle-
treated cU)/db mice. However, the quantity of GLUT4 transporter within the cytoplasm at 
to the vehicle-treated, db/db animals (1.55+0.22 vs. 0.624+0.22 OD units, respectively; 
p<0.01), and approached values of normal, vehicle-treated animals (1.50+0.22 vs. 
1.488+0.36, respectively; p>0.05). These data suggest that T3 treatment plays a role in 
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Figure 3. GLUT4 quantity associated with plasma membrane ofadipocytes ofnormal
 
{+/db) and diabetic (db/db) mice treated with T3 (0, 100, 200, and 500 ng/g BW).
 
Comparisons are between phenotypes at the given dose(Values are±SEM,n=5).
 
The baseline GLUT4quantity associated with the plasma membrane ofadipocytes in
 
vehicle-treated +/db mice,shown in Figure 3,was approximately 0.502±0.03 OD units; T3
 
did not change this value at any dose(0.470±0.01,0.600±0.17OD units, and 0.406±0.10
 
OD units respectively, p>0.05). These values represent the normal expression levels of
 
GLUT4 transporters at the plasma membrane. The baseline expression ofthe GLUT4
 
transporters associated with the plasma membraneofadipocytes from vehicle-treated,db/db
 
mice was approximately50%less than normal mice(0.262±0.05 vs. 0.502±0.03 OD units,
 
respectively; p<0.05). Thereplacement dose of100ng T3/gBW restored membrane-bound
 
GLUT4levelsto those ofnormal,vehicle-treated animals(0.474±0.01 vs. 0.502±0.03 OD
 
units, respectively; p>0.05). Atthe hyperthyroid dose(200 ng Tg/g BW),the quantity of
 
GLUT4 transporter associated with the plasma membrane increased dramatically in
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comparison to vehicle-treated mice (0.262±0.05 vs. 0.986±0.55 OD units,
 
respectively; p<0.05) and exceeded that of +/£ZZ' mice treated with the same dose
 
(0.986±0.28 vs.0.600±0.17,respectively; p<0.05). However,the GLUT4 quantity in db/dh
 
mice at the supraphysiological dose was indistinguishable from that of normal animals
 
(0.428±0.14 vs.0.406±0.IG OD units,respectively; p>0.05). The membrane-bound GLUT4
 
quantity of db/db mice increased with the replacement and hyperthyroid doses in
 
conjunction with decreases in cytoplasmic GLUT4transporter content. This redistribution
 
suggests that Tjmay play an important role in supporting vesicular translocation.
 
The proportion oftotal GLUT4transporters associated with the plasma membrane
 
was assessed in adipocytes of+/<iZ» md db/db mice in order to determine whether T3 might
 
play a role in regulating GLUT4 transporter cellular distributions and are reported as a
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Figure 4. Fraction ofGLUT4 transporters associated with plasma membrane of adipocytes 
ofnormal (+/db) and diabetic (db/db) mice treated with T3 (0, 100, 200, and 500 ng/gBW). 
Comparisons are between phendtypes at the giveh dose (Values are ± SEM, n=5). 
30 
percentage (Figure 4). The plasma membranes of vehicle-treated +/db mice contained
 
26±3%ofthe total GLUT4 quantity. The GLUT4transporter percentage associated with
 
the membrane remained unchanged at all doses of Tjin comparison to vehicle-treated
 
animals. These data suggest that the distribution of GLUT4 transporters between the
 
cytoplasmicfraction and plasma membrane is not under control by Tj, at least with respect
 
to physiological doses present in +/db animals. In vehicle-treated db/db mice, the
 
percentage ofGLUT4transporters associated withthe plasma membrane ofadipocytes was
 
29.5±1%(Figure 4). In micethat received 100ng Tj/gBW dose,the percentage ofGLUT4
 
increased approximately 2-fold in comparison to vehicle-treated db/db animals(59±2% vs.
 
29.5±1% respectively, p<0.01)and subsequently increased again with 200 ng Tj/gBW to
 
76±7%(p<0.01). With 500 ng Tj/g BW,the percentage ofGLUT4 associated with the
 
membrane significantly decreased in comparisonto db/db mice receiving hyperthyroid doses
 
(21.6±6% vs.76±7%,respectively; p<0.01),and approximate values observed in +/db mice
 
(21.6±6% vs.26±3%,respectively;p>0.05). In vehicle-treated animals,the fraction oftotal
 
GLUT4 associated with the plasma membrane is equal in both +/db and db/db mice
 
suggesting a proportionate distribution. T3treatment does not alter GLUT4redistribution
 
in +/db animals. But,in db/db mice which are T3 resistant and functionally hypothyroid,T3
 
stimulated a redistribution with proportionately more GLUT4 residing in the plasma
 
membrane. This represents thebasal ejEFect ofT3on GLUT4trafficking htcmstdb/db mice
 
are "normalized" at supraphysiological T3 doses. These data show that T3 treatment
 
increases the percentage ofGLUT4transporters associated with the plasma membrane of
 
adipocytes in db/db mice. Thus,T3 plays a role in GLUT4transporter translocation.
 
31
 
 +/db
 
ft. 0.70
 
ft 065
 
db/db
 
Tjdose(ng/g BW)
 
Figure 5. Total GLUT4transporter content in myocytes ofnormal{+/db)and diabetic
 
{db/db)mice treated with Tj(0, 100,200,and 500 ng/g BW). Comparisons are between
 
phenotypes at the given dose(Values are±SEM,n=5).
 
Skeletal muscle is the major thermogenic tissue and the most metabolically active. It
 
is insulin-responsive and accountsfor85%ofserum glucose uptake in the body. Therefore
 
it is important to examine the GLUT4transporter profile in myocytes. The total GLUT4
 
quantity was determined in the myocytes of+/db and db/db mice(Figure 5). The total
 
GLUT4transporter quantity in vehicle-treated +/db animals was0.58±0.04OD units and
 
this subsequently increased with thyroid hormone treatment with the maximal response
 
occurring at20G ng Tj/gBW(0.744±0.020D units). However,at the supraphysiological
 
dose,the total GLUT4transporter quantity significantly decreased relative to mice receiving
 
200 ng Tg/gBW(0.664±0.04 vs. 0.744±0.02 OD units, respectively; p<0.05). Although
 
not significant at p<0.05,the total GLUT4 quantity observed in animals receiving 500 ng
 
Tj/gBW wasapparently greater than vehicle-treated +/<i& mice(p<0.10). The increase in
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total GLUT4transporter quantity suggests that Tjinduces GLUT4transporter expression
 
in normal animals.
 
The total GLUT4transporter quantity in myocytes ofvehicle-treated animals
 
was similarto that ofvehicle-treated normal animals(0.572±0.03 vs. 0.580±0.04 OD units,
 
respectively; p>0.05). Treatment with 100 or 200 ng Tj/gBW caused the total GLUT4
 
quantity to increase. Atthe supraphysiological dose(500 ng Tg/g BW),the total GLUT4
 
transporter quantity in db/db mice approached values observed in vehicle-treated +/db
 
animals(0.594±0.02 vs. 0.58±0.04 OD units, respectively; p>0.05). This suggests that
 
someGLUT4induction at 100 and 200 ng T3/gBW doses occurred with thyroid hormone
 
treatment and T3 had a normalization effect on the total GLUT4 transporter quantities.
 
Also, attenuation responses were observed with supraphysiological T3 treatment. These
 
responses in db/db mice paralleled the pattern observed in +/db animals but always to a
 
lesser degree.
 
The distributions ofGLUT4transportersin the cytoplasm and plasma membrane were
 
also determined in skeletal muscle(Figures6 and 7)and an expression pattern similar to
 
adipose tissue was observed. The baseline expression ofcytoplasmic GLUT4transporter
 
in myocytes ofvehicle-treated(0 ng T3/g BW)+/db animals was 0.268±0.03 OD units
 
(Figure 6). The cytoplasmic GLUT4 transporter quantity in myocytes of +/db xmcQ
 
increased linearly with treatments of100 and 200 ng T3/g BW. Treatment with 500 ng T3/g
 
BW also increased cjdoplasmic GLUT4butto a lesser degree(0.402±0.03 OD units).
 
In db/db mice, the baseline expression of cytoplasmic GLUT4 in myocytes was
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Figure6. Cytoplasmic content ofGLUT4transporters in myocytes ofnormal{+/db)and
 
diabetic{db/db)mice treated with Tj(0, lOG,200,and 500 ng/g BW). Comparisons are
 
between phenotypes at the given dose(Values are±SEM,n=5).
 
0.326±0.03 OD units(Figure 6). The cytoplasmic GLUT4quantity in vehicle-treated db/db
 
mice was not significantly different Xhm +/db animals but the quantity of cytoplasmic
 
GLUT4mdb/db mice decreased with all dosesofthyroid hormone(p<0.05). However,the
 
cytoplasmic GLUT4 content transporters ofdb/db mice approximated values ofvehicle-

treated +/db mice when treated with 500 ng Tj/g BW.
 
The baseline GLUT4transporter expression in the plasma membrane ofvehicle-treated
 
+/£/&mice was 0.312±0.03 OD units (Figure 7). The quantity of GLUT4 glucose
 
transporters associated with the plasma tnembrane in these animals decreased with thyroid
 
hormone treatment (p<0.05). In vehicle-treated db/db mice, the baseline GLUT4
 
transporter quantity wasless than vehicle-treated +/db mice(0.246±0.02 vs. 0.312±0.03
 
OD units,respectively; p<0.05). In contrast to normal animals,thjToid hormonetreatment
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Figure 7. GLUT4quantity associated with plasma membrane ofmyocytes ofnormal{+/db)
 
and diabetic(db/db)mice treated with T3(0, 100,200,and 500 ng/g BW). Comparisons
 
are between phenotypes at the given dose(Values are±SEM,n=5).
 
increased the quantity ofGLUT4 transporters associated with the plasma membrane in
 
db/db mice. The GLUT4 quantity with supraphysiological T3 doses approached values of
 
normal, vehicle-treated animals (0.302±0.02 vs. 0.312±0.03 OD units, p>0.05) which
 
suggests that T3 normalized db/db mice. The observed increases in GLUT4transporters
 
associated with the plasma membrane as the cytoplasmic pool decreases suggests that in
 
db/db mice vesicular translocation occursin response to thyroid hormone administration.
 
Tofurther evaluate the possibilities ofTj-induced vesicular translocation in myocytes,
 
the quantity ofGLUT4transporters associated with the plasma membranes were assessed
 
and reported as a proportion ofthe total cellular GLUT4content. In vehicle-treated +/db
 
animals,the percentage ofGLUT4 was approximately 54±4%(Figure 8). Normalmice
 
showed dose-dependent decreasesin the GLUT4transporter percentage associated with the
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Figure 8. Fraction ofGLUT4 associated with plasma membrane ofmyocytes ofnormal
 
{+/db) and diabetic {db/db) mice treated with Tj(0, 100, 200, and 500 ng/g BW).
 
Comparisons are between phenotypes at the given dose(Values are±SEM,n=5).
 
plasma membrane up to 200 ng Tj/g BW. The percentage of GLUT4 transporters
 
associated withthe plasma membrane ofmyocytesin vehicle-treated db/db animals wasless
 
than the vehicle-treated +/db mice(43.3±3% vs. 54±4%,respectively; p<0.05). Treatment
 
with thyroid hormoneincreased the percentage ofGLUT4transporters associated with the
 
plasma membrane at all doses in db/db animals and surpassed the percentage ofGLUT4
 
transporters associated with the plasma membrane of^/db mice atthe 100 ng T3/gBW dose
 
(58.2±6% vs.43±9%,p<0.01). However,at the supraphysiological dose,the percentage
 
ofGLUT4transporters associated with the membrane approached the percentage values
 
observed in vehicle-treated +/db animals (57.2±7% vs. 54±8%, p>0.05). These data
 
suggest that T,stimulates GLUT4 transporter translocation to the plasma membrane of
 
myocytesin db/db mice. The significant increase in the percentage ofGLUT4transporters
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associated withthe plasma membrane observed in myocytes from db/db mice is important
 
since this may facilitate increased glucose uptake in skeletal muscle.
 
T3treatment regulated the induction and vesicular translocation mechanismsin adipose
 
tissue oidb/db animals. T3 did not induce GLUT4 expression in +/db mice since total
 
GLUT4 expression decreased with treatment but did induce GLUT4 expression in db/db
 
mice. Thus,the decrease in cytoplasmic GLUT4that was observed within adipocytes of
 
+/db animals may be attributed to either decreased induction of the GLUT4 glucose
 
transporter or decreased plasmamembraneintemalization. In vehicle-treated +/db animals,
 
the cytoplasmic GLUT4quantity decreased with T3whereasin db/db mice it increased. The
 
decreased cytoplasmic GLUT4 transporter quantity observed in vehicle-treated db/db
 
animals may reflect a problem with the induction process. Vehicle treatment in db/db mice
 
represents "hypothyroid" concentrations and treatment with T3 restores the animal to
 
functionally euthyroid T3 levels. Thus, with T3 treatment, GLUT4 transporter levels
 
approximatethose ofnormal animals. The plasma membrane associated transporter quantity
 
in normal mice was unaltered with T3 doses. Although translocation ofthe cytoplasmic
 
GLUT4towardsthe plasma membrane wasobserved in db/db animals with thyroid hormone
 
treatment, a decrease in membrane-associated GLUT4 transporter quantity with a
 
concomitantincrease in the c54oplasniic pool was observed at the supraphysiological doses
 
which may represent either attenuated T3 responsiveness or accelerated intemalization of
 
GLUT4transporters.
 
Alterations in skeletal muscle GLUT4 expression have been reported in NIDDM
 
subjects. However, the current study reports induction ofGLUT4transporters by T3in
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translocation in myocytes ofdb'db animals. A decrease in the cytoplasmic pool with a
 
concomitant increase in the GLUT4 transporter quantity associated with the plasma
 
membrane was also observed. This suggests that Tj regulates GLUT4 transporter
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Figure 9. Core body temperatures of normal {-v/dh) and diabetic {db/dh) mice treated
 
with Tj(0,100,200,and 500 ng/gBW).
 
dose(Values are± SEM,n=5).
 
38
 
  
temperatures of+/<i&mice on day 10. These data confirm that T3treatment increasescore
 
body temperatures in normal mice and represent the normalthermogenic response.
 
The core body temperatures ofvehicle^treated db/db mice were less than those of
 
normal animals(29.52±0.23''G vs. 30.44±0.10°C,respectively; p<0.01). Thyroid hormone
 
treatment induced dose-dependent increases in core body temperatures ofvehicle-treated
 
db/db animals with a maximalresponse being reached at200 ng Tj/gBW. The 500 ng Tj/g
 
BW dose caused no further change. These data show that the core bodytemperatures of
 
vehicle-treated mice are less than +/db mice and suggest that T3treatment increases
 
core body temperatures in db/db mice to levels of+/db animals. Core bodytemperatures
 
ofdb/db mice were,however,lowerthan similarly treated +/db mice at all doses suggesting
 
Tjhyporesponsiveness and/or reduced thermogenic capacity.
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Figure 10. Daily core body temperatures ofvehicle-treated normal(+/db)and diabetic
 
{db/db)mice. Comparisons are between phenotypes at the given day(Values are± SEM,
 
n=5).
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 Figure 10 shows that the core body temperatures of vehicle-treated +/db mice
 
gradually declined throughoutthe study resulting in day 10 values less than those observed
 
on day 1(32.4±0.19°C vs. 30.44±0.WC,respectively; p<0.05)while vehicle-treated
 
animals showed a similar but not statistically distinguishable decrease (30.5±0.11°C vs.
 
29.5±0.23°C,respectively, p>0.05). Atemperature decrease observed in +/<iZ> animals was
 
unexpected and cannot be explained using available data.
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Figure 11. Daily core body temperatures of normal (+/db) and diabetic (db/db) mice 
treated with 100 ng Tj/g BW. Comparisons are between phenotypes at the given day 
(Values are ± SEM, n=5). 
The core body temperatures of mice treated with 100 ng Tj/g BW remained 
unchanged through day 6, but decreased on days 7 through day 10 (Figure 11). Indb/db 
animals receiving the replacement dose, core body temperatures increased and a maximal 
response was observed on day 6. In a pattern similar to +/db mice, the temperatures in 
db/db animals decreased on days ? through day 10. The fluctuations in temperature may 
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be attributed to induced stress resulting from handling and methods in obtaining colonic
 
temperature readings, however this was not tested.
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Figure 12. Daily core body temperatures ofnormal(+/db)and diabetic {db/db)xmcQ
 
treated with 200 ng Tj/g BW. Comparisons are between phenotypes at the given day
 
(Values are± SEM,n=5).
 
Daily core bodytemperatureswererecorded to assess the chronology ofthermogenic
 
responses. Figure 12showsthe responses of+/ri& and mice treated whh200 ng Tg/g
 
BW and these representthe mammal metabolicresponses recorded for alltremment groups.
 
The maximal response was observed on day 4(32.52±0.16°C) after which core body
 
temperatures continued to decrease Until day8 where they remained constantuntil day 10
 
(31.04±0.18°C). ladb/db mice,the baseline core body temperatures were considerably less
 
than those of normal mice, but T3 treatment caused daily increases in core body
 
temperatures with the maximal response being observed on day 6. Temperatures then
 
decreased until day9where they remained constant through day lOi. Similar chronological
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responses to Tj-induced thermogenesis were observed in both +/dh and db/db mice.
 
However,
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Figure 13. Daily core body temperatures of normal(+/dh) and diabetic(dh/dh) mice
 
treated with 500 ng Tj/g BW. Comparisons are between phenotypes at the given day
 
(Values are± SEM,n=5).
 
The core bodytemperaturesfrom -Mb and dh/dh mice treated with 500 ng T^/g BW
 
were also recorded on days 1 through 10(Figure 13). The temperature changes in these
 
animals paralleled those observed in mice treated with 200 ng T,/g BW. The core body
 
represent the heat that is dissipated. As core body temperatures increased in response to
 
on
 
temperatures occurred on days 7-10. Excess heat is dissipated on days7through 10.
 
Mh and dhMh mice were recorded on days 7-10. Figure 14 shows that the radiant
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temperatures of+/(i& mice increased in response to
 
Tj/gBW. There was an increase in radiant heat as the body core temperatures decreased.
 
As core body temperaturesof+/db and db/db mice decreased bn day7oftreatment,the
 
doses. . .
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Figure 14. 
To (0, 100, 200, and 500 ng/gBW). Comparisons are between phenotypes at the given dose 
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The radiant temperatures oidb/db mice increased inresponse to T3 at all doses (Figure 
14). 
animals (30.96±0.I4°C vs. 31.56±0.12''C, p^O.05). The maximal response occurred at 500 
ng Tj/gBW at wliich the radiant temperature was also greater than f /db mice. These data 
show that Tj induces thermogenesis inboth /db and animals. The increase in radiant 
temperature as the core body temperatures decreased occurred in order to dissipate the 
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excess heattothermoregulatethe coretemperature. This pattern was also observed in +/db
 
•niice..: ..
 
The radiant temperaturesfrom !/dh mice treated with vehicle and 100,200,and 500
 
ng Tj/gBW were recorded on days7through 10. An increase in radiant temperature was
 
observed atthe 100ng Tg/g BW dose in \ /dh and dh/dh animals on days7and 8(data not
 
shown),a pattern similar to the group ofmice treated with 200 ng Tj/g BW. However,
 
radiant temperatures of+/dh mice decreased on days 9-10 and were not different than
 
temperatures recorded on day 7 whereas radiant temperatures in dh/dh mice increased
 
through day 10.
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200 ng Tj/g BW. Comparisons are are±
 
n=5). . \
 
are shown since maximalthermic responses were observed at these doses. Figure 15 shows
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 that the radiant temperature in '-/dh mice on day 7 was 34.1±0.10''C and continued to
 
increase until a maximal response was observed on day 10(36.68±0.22"C). In dh/dh mice,
 
radiant temperatures increased with Tg treatment and the maximal response was observed
 
These observations suggest that, with T,treatment, radiant temperatures ofdb/dh mice
 
approach normal and implythatdh/dh animals are utilizing as much energy as -\-/dh animals
 
to drive thermogenesis.
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Figure 16. Radianttemperatures ofnormal{+/dh)and diabetic(dh/dh)mice treated with
 
500 ng Tj/g BW. Comparisons are between phenotypes at the given day(Values are±
 
SEM,n=5).
 
The radiant temperatures of -/dh mice treated with 500 ng Tj/g BW were also
 
tothat observed in mice treated with 200 ng T3/gBW. The day7radiant temperatures of
 
normal animals were 34.96±0.24"C with the maximal response observed on day9 and a
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 decrease on day 10. In db/db mice,the radianttemperature on day7was34.94±0.16°C and
 
the maximal response observed on day 10 was greater than that of +/(i6 animals
 
(36.88±0.13''C vs. 35.76±0.08''C, p<0.05). These observations suggest that Tjtreatment
 
increases the radiant temperatures ofdb/db mice beyond those ofnormal animals implying
 
that greater energy is being utilized and that db/db animals are dissipating more heatthan
 
+/db mice. The concomitant decreasein core bodytemperature observed in +/db mA db/db
 
animals is likely due to thermoregulation in order to maintain alow core temperature.
 
Serum Glucose Determination
 
Serum glucose concentrations were evaluated in +/db and db/db animals in order to
 
determine if thyroid hormone treatment influenced serum glucose levels. The baseline
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Figure 17. Serum glucose concentrations of normal(+/<i&) and diabetic {db/db) mice
 
treated with Tj(0, 100,200,and 500 ng/g BW). Comparisons are between phenotypes at
 
the given dose(Values are± SEM,n=5).
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glucose levels in vehicle-treated +/<5?Z> mice were 260.2±25.3 mg glucose/dL and these
 
remained relatively constant with T3treatment(Figure 17). In db/db mice,the baseline
 
glucose concentration was 592.0±63.0 mg glucose/dL and this is considered severely
 
hyperglycemic. Serum glucose levels decreased with T3 treatment in a dose-dependent
 
fashion. At 500 ng Tj/g BW,serum glucose levels decreased approximately 42% when
 
compared to vehicle-treated mice(592.0±63.0 vs. 344.5±31.4 mg glucose/dL,respectively;
 
p<0.01)which indicates that T3treatment improved the glycemic status in db/db animals.
 
Respiratorv Quotient(ROIDetermination
 
The respiratory quotient,RQ,(mlCO2/mlO2)was monitored daily in +/db and db/db
 
mice over a nine day period in order to determine the effect T3 treatment might have on
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Figure 18. Respiratory quotients(RQ)ofnormal(+/db)and diabetic{db/db)mice treated
 
with T3(0,100,200,and 500ng/gBW). Comparisons are between phenotypes at the given
 
dose(Values are± SEM,n=5).
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metabolic substrate utilization. The RQ of +/db mice treated with 0 ng T3/g BW was
 
0.78±0.03 (Figure 18) which suggests that a combination of proteins, lipids and
 
carbohydrates were potentially being used as the metabolic substrate. With T3treatment,
 
the RQ value decreased to 0.74±0.01 which suggests a shift toward more fat or protein
 
catabolism. In vehicle-treated db/db mice, the RQ was 0.87±0.05 (Figure 18). This
 
indicates that substantially more carbohydrates were being used as a metabolic substrate
 
than is typically used by +/db animals. With increasing doses ofthyroid hormone,theRQ
 
decreased significantly. Diabetic mice treated with 100 ng T3/g BW had a respiratory
 
quotient that wasless than vehicle-treated animals(0.78±0.02 vs. 0.87±0.05,p<0.05)and
 
suggeststhatthe primary substrate being utilized had shifted from carbohydratesto fats or
 
proteins. The RQ values of db/db mice treated with either 200 or 500 ng T3/g BW
 
approached those ofvehicle-treated +/db animals(0.76±0.03 vs. 0.74±0.03,p>0.05)and
 
indicates that the db/db mice were undergoing fat catabolism. This also suggests that the
 
diabetic mice have undergone normalization in substrate utilization.
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CHAPTER FOUR: DISCUSSION
 
The insulin-regulatable GLUT4transporter is expressed in skeletal muscle, adipose
 
tissue,and cardiac muscle(Pessin and Bell 1992;Mueqkler 1994;Stephens and Pilch 1994)
 
and regulates glucdsd uptake in those target tissues. The present study investigated whether
 
thyroid hormonetreatment could restore the insulin effects on GLUT4glucose transporter
 
induction and/ortranslocation intheinsulin-resistant mouse. This effect was assessed
 
by examining the total GLUT4 quantity as an indicator ofthe induction process and the
 
cellular GLUT4 distributions Which represent translocation within the cell. These
 
phenomena were evaluated in lean C57BL/KsJ +/db mice and obese-diabetic G57BL/KsJ
 
db/db nice,which are insulin-resistant(Hummeletal. 1966), Ts-resistant, and functionally
 
hypothyroid(Fehn er a/. 1988).
 
Matthaei etal.(1995)shoWed that the total GLUT4glucose transporter quantity in
 
adipocytes ofmale Sprague-Dawley fats decreased in hypothyroid animals, but increased
 
in hyperthyroid rats. These results agree with data presented in this study since the
 
functionally hypothyroid and Tj-resistant db/db mice are broughtto functionally euthyroid
 
status using hyperthyroid doses of T3. The total GLUT4 quantity was assessed in the
 
adipocytes of and db/db mice in order to determine ifadministration ofT3 stimulated
 
GLUT4induction. TotalGLUT4transporter quantity in +/<i& niice remained unchanged
 
with increasing doses ofT3 which suggests that induction the GLUT4 transporter is not
 
likely under direct regulation at normal physiologic concentrations of T3. However,
 
attenuation wasobserved atthe maximaldose ofT3. In mice,which are T3-resistant
 
and functionally hypothyroid,the total GLUT4 quantity was50% that ofvehicle-treated
 
+/db animals and this increased 2-fold with T3treatment and approached levels equivalent
 
to those ofvehicle-treated +/db animals(Figure 1). Thefindings in this study are consistent
 
with results showing that T3increases total GLUT4 protein expression(Cask etal. 1990).
 
This suggests that T3 stimulates GLUT4 induction and normalizes GLUT4 quantities in
 
db/db mice. A reduction in the degradation rate to accountfor increased GLUT4cannot,
 
however,be discounted.
 
Zorzano etal.(1996)showed in STZ-induced diabetic(insulin-deficient)Wistar rats
 
thatthe quantity ofGLUT4 decreased in the cytoplasm ofadipocytes and increased in the
 
plasma membrane with increased insulin concentrations. This author suggests that insulin
 
promotes redistribution ofthe glucose transporterto the plasma membrane. Although these
 
results explain the established effects ofinsulin,the current study addresses thyroid hormone
 
effects and the potential restoration ofinsulin action in a modelfor NIDDM. In the current
 
study, T3 mimics the effects Zorzano er al.(1996)reported for insulin action. Zorzano's
 
results are in agreement with the results observed in the +/db mice from this study since
 
these animals remain insulin-responsive. Gytoplasmic and membrane-bound GLUT4 in
 
adipocytes of+/db mice remained Constant with T3 treatment and only the cytoplasmic
 
portion decreased with supraphysiological doses(Figures2and 3). This represents normal
 
expression, GLUT4 transporter recycling, and regulation in a normal endocrine
 
environment. However,the decreased cytoplasmic GLUT4 at the 500 ng Tj/gBW dose
 
suggests increased degradation of membrane components or attenuation of GLUT4
 
synthesis. Such attenuation is a blunted response typically observed within systems that
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have been pushed to physiological extremes.
 
Previous studies on adipocytesfrom insulin-deficient diabetic rats(Kahn etal. 1989;
 
Bergeretal 1989)and in studies using 3T3-L1 adipocytes cultured in vitro without insulin
 
(Calderhead etal. 1990),showed that cytoplasmic GLUT4 quantities were less than those
 
ofnormalrats and insulin-treated cells, respectively. Decreased expression ofthe GLUT4
 
transporter has also been documented in NIDDM patients as well as in diabetic animal
 
models(Koranyi etal 1990;Kahn 1996). The decrease in cytoplasmic GLUT4number
 
reduces their availability to be mobilized to the plasma membrane and could explain the
 
lower plasma membrane content. It has also been reported that insulin-stimulated GLUT4
 
translocation is impaired in adipocytes fi^ Om NIDDM individuals (Ciaraldi al 1991).
 
However,the mechanism by which translocation is regulated has not yet been explained and
 
has recently received much attention as being the potential site ofregulatory defects(Kahn
 
1996). The current study showed that cytoplasmic GLUT4in vehicle-treated db/db mice
 
was50% less than vehicle-treated +/£/& mice. This quantity decreased in response to T3
 
treatment but increased 2-fold with the 500 ng T3/g BW dose and therefore approached
 
levels ofvehicle-treated +/db mice(Figure 2). Ascytoplasmic GLUT4is disproportionately
 
depleted, a concomitant increase in the quantity ofmembrane-bound GLUT4is observed
 
which approaches that ofvehicle-treated +/db mice(Figures 2,3). This suggests that T3
 
facilitates GLUT4translocation fi-om the cytoplasm to the plasma membrane and normalizes
 
GLUT4 within adipose tissue offunctionally "hypothyroid" animals.
 
The proportion ofGLUT4glucose transporters associated with the plasma membrane
 
was calculated in +/db and db/db miceto determine ifthyroid hormone administration plays
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a role in the trafl&cking ofthe GLUT4transporter, specifically in the translocation process.
 
Thistype ofanalysis has notbeen reported previously,thus there are no studies with which
 
to comparethe current data. The percent ofthe GLUT4transporter population associated
 
with the plasma membrane ofadipocytes in +/db mice did not change with T3 treatment
 
(Figure 4). Thyroid hormone either did not alter the GLUT4 transporter turnover or it
 
equally affected the rates ofintemalization and association ofGLUT4transporters with the
 
plasma membrane. Although the absolute amount ofmembrane-bound GLUT4in db/db
 
mice wasless than in +/db mice,the percent ofGLUT4glucose transporters associated with
 
the plasma membrane was similar to that of+/db mice(Figure 4). This shows that the
 
membrane-bound GLUT4 quantity in relation tO the total GLUT4 in db/db mice is
 
proportional to that of+/db animals, thus,the percentage is scaled down proportionately
 
in db/db mice. In db/db animalstreated with T3,the percent ofGLUT4associatedwith the
 
plasma membraneincreased suggesting that T3may regulate GLUT4translocationfrom the
 
cytoplasm to the plasma membrane. Since the final proportions approached those of+/db
 
mice, it appears that T3 normalizes the GHJT4 quantity associated with the plasma
 
membranes ofdb/db mice. Thyroid hormone does not induce the synthesis ofadditional
 
GLUT4in +/db mice nor isthe cellular distribution affected. As a result ofovercoming T3
 
resistance in db/db mice,T3inducesGLUT4synthesis resulting in increased cellular GLUT4
 
content. The cytoplasmic population consequently is redistributed towards the plasma
 
membrane suggesting that T3 restores the translocation process.
 
GLUT4transporter expression and subcellular distribution were assessed in myocytes
 
because skeletal muscle is a metabolically active tissue which utilizes approximately85%
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oftotal^cos6^ail^l6^ is tlie m^opsiteforglucose disposaland isthe
 
majof site ofinsulin:resistance witlun NiDD|M%bjects nr/. 1996). Thetotal
 
GrLUT4 quantity was assessed in the myocytes of+/db and db/dh mice to deternune if
 
thyroid hormone administration stimulated GLUT4induction. Total GLUT4 quantity in
 
\ /dh miceincreased with T3treatment at physiological doses butto a lesser degree with the
 
supraphysiological dose. This shows that Tjfacilitates GLUT4transporter induction. In
 
vehicle-treated db/db mice, the total GLUT4 transporter quantity was similar to that of
 
vehicle-treated -/db animals and total GLUT4 quantity also increased with T,treatment
 
showing that Tjinduces the GLUT4transporter.
 
The current study proposes a model whereby T,either overcomes thyroid hormone
 
resistance and restoresthe insulin response in target tissues ofdb/db mice or T,has a direct
 
effect in GLUT4 transporter regulation. If the insulin response is restored with Tj
 
treatment,the resultsfrom the current study then contradict published reports which show
 
thatGLUT4transporter expression within skeletal muscle remains unchanged in response
 
to insulin treatments(Kahn 1996;Hainhault etal. 1991;Pedersen etal. 1990). A possible
 
reasonfor this discrepancy is that all animal and human subjects were fasted at least8 hours
 
prior to testing and fasting causes a decrease in thyroid hormone levels thereby rendering
 
the animals hypothyroid. Weinstein el al.(1991) showed that T,could induce GLUT4
 
expression in skeletal muscle ofhypothyroid non-diabetic animals that were restored to
 
euthyroid status. Sincethe animals werefasted priorto tissue collection,the GLUT4 values
 
and thyroid levels are not accurate representations ofanimalsin a non-fasting state. Atthe
 
supraphysiological dose,total GLUT4in myocytesofdb/db mice approached GLUT4levels
 
found in vehicle-treated+/<i& animals (Figure 5). This suggests that total GLUT4 is
 
normalized in dh/db mice that have overcome thyroid hormone resistance. Although total
 
GLUT4quantitiesin vehicle-treated +/db and db/db mice were not different(Figure 5),the
 
subcellular distributions were different in the two phenotypes(Figures6,7). However,T3
 
treatment allows for "normal" GLUT4 expression and a more appropriate distribution of
 
subcellular GLUT4 quantities. These data show that T3 stimulates GLUT4induction and
 
likely plays a role in either the transcriptional or translational processing ofthe GLUT4
 
glucose transporter.
 
The quantity ofcytoplasmic GLUT4in myocytes of+/db mice increased in response
 
to thyroid hormone treatment and these results are consistent with the published literature
 
(Casla et al. 1990;Weinstein etal. 1991;Weinstein etal. 1994). Induction ofGLUT4has
 
been established above, but the increased cytoplasmic quantity can also reflect increased
 
intemalization ofplasma membrane components(Figure 6). This response contrasts with
 
observations made in adipocytes of+/db animals and suggests tissue-specific responses to
 
T3. The membrane-bound GLUT4 in +/db mice decreased with T3. This suggests
 
attenuation phenomena orincreased GLUT4transporter intemalization as was seen with the
 
adipocytes of +/db mice. Based on the observations within myocytes, T3 appears to
 
regulate GLUT4transporter induction and vesicular translocation at a basal level whereby
 
T3 exhibits its permissive action under normal physiological conditions.
 
Several studies have shown that cellular GLUT4expression levels(either protein or
 
mRNA)are unchanged inthe skeletal muscle ofdiabetic subjects(Kahn 1996;Hainhault et
 
al 1991;Pedersen etal 1990)including the quadriceps of5 week-old db/db mice(Koranyi
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et al. 1991). In each ofthese studies, only the plasma membrane-associated content of
 
GLUT4glucose transporters has been shown to be altered in skeletal muscle. However,
 
results from the current study show that the cytoplasmic GLUT4in db/dh mice is greater
 
thanthe cytoplasmicGLUT4contentfound within ^ /dh mice and these quantities decrease
 
inresponseto Tj. This indicates that the pool ofcytoplasmic GLUT4in myocytes of8-10
 
week old db/db mice is regulated by Tj. These results are contrary to reports ofunalterable
 
GLUT4 expression in quadriceps of5 week old mice. This discrepancy can be
 
attributed to the age differences ofthe mice. Fehn etal(1988)reported that the onset of
 
a defect in Tg responsiveness occurs after6 weeks ofage thus Koranyi etal(1990)missed
 
the onset period and obtained results from animals not yet displaying the Tg-resistance.
 
Also, a concomitant disproportionate depletion in cytoplasmic GLUT4 quantities was
 
observed while membrane-bound GLUT4increased in db/db mice(Figures6,7). This was
 
similar to the pattern observed in adipocytes and indicates that T3 may regulate GLUT4
 
translocatioh from the cytoplasm towards the plasma membrane. This observation is
 
extremelyimportant since skeletal muscle requires the GLUT4transporter for the majority
 
ofglucose uptake. Although T3regulation ofGLUT4translocation has not been reported
 
in the literature,the results reported here are consistent with the depletion ofa cytoplasmic
 
vesicular poolin response to a hormonal signal(Weinstein etal 1994). Therefore, T3 is
 
herein proposed as a regulator ofGLUT4translocation process.
 
At the supraphysiological dose ofT3(500 ng/g BW),the membrane bound GLUT4
 
transporter quantity in db/db mice decreases, although it still remains greater in comparison
 
to the vehicle-treated counterpart. As the membrane-bound quantity decreases
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(approaching values similar to the baseline expression levels of+/db vehicle-treated mice),
 
the quantity ofcytoplasmic GLUT4-containing vesicles increases also approaching values
 
similarto +/db vehicle-treated mice. This suggests a normalization phenomenon within the
 
skeletal muscle in response to thyroid hormone treatment.
 
The current study establishes that Tjincreases GLUT4transporter induction because
 
an increase is seen in the total cellular quantity ofGLUT4transporters. These data agree
 
with the findings of Casla et al. (1990) and Weinstein et al. (1991). More recently,
 
Torrance et al.(1997)showed that Tjregulates GLUT4expression at the transcriptional
 
levelin one muscle fiber type and increased both membrane-bound GLUT4 quantities and
 
GHJT4mRNA. However,Torrance etal.(1997)failed to recognize that T3 regulates the
 
redistribution ofthe GLUT4transporterfrom the cytoplasm to the plasma membrane. This
 
redistribution ofGHJT4transporters towards the plasma membrane is important since it
 
may be the pathwayfor increased cellular glucose uptake.
 
In normal mice, the percent ofthe GLUT4 transporter associated with the plasma
 
membrane ofmyocytes decreased with thyroid hormonetreatment and shows that T3 altered
 
GLUT4 transporter turnover(Figure 8). Perhaps overloading the system with an excess
 
number ofGLUT4 transporters surpasses the quantity of docking complexes available
 
within the cell leading to accumulation in the cytoplasm. Alternatively, intemalization of
 
membrane components may be accelerated as part ofanincreased recycling rate phenomena.
 
The percent of GLUT4 glucose transporters associated with the plasma membrane of
 
vehicle-treated db/db mice wasless than that ofvehicle-treated +/<i6 mice(Figure 8). This
 
quantity increased with thyroid hormone treatment and indicates that T3regulates GLUT4
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vesicular translocation fromthe cytoplasm towardsthe plasma membrane. Thisis extremely
 
important since the increased percent ofGLUT4transporters associated with the plasma
 
membrane indicates translocation and docking and suggests a greater probability that
 
GLUT4 transporters have fused with plasma membrane. Increased fusion of GLUT4
 
transporters with the plasma membrane of myocytes would facilitate increased glucose
 
uptake which would providethe substrate for increased thermogenic activity in the skeletal
 
muscle. Althoughthese data show that T3 regulates the translocation mechanism from the
 
cjtoplasm to the plasma membrane,one cannot say that the GLUT4transporters within the
 
vesicle membrane are incorporated into the plasma membrane. Thus,the vesicular fusion
 
mechanism warrants fiirther investigation.
 
The current study establishes that T3 plays a role in GLUT4transporter regulation.
 
Thyroid hormoneinduced the GLUT4transporter in both adipocytes and myocytes,but to
 
varying degrees. Thisshowsthe tissue specific responsesto T3in relation to GLUT4. Also,
 
T3promoted the translocation ofcytoplasmic GLUT4towardsthe plasma membrane in both
 
myocytesand adipocytes and thus contributed to the increased plasma membrane GLUT4
 
content. This is particularly important in relation to NIDDM since this increased quantity
 
may facilitate increased glucose uptake within these cells. The increased glucose uptake
 
would thus providethe cells, particularly myocytes with a substrate that can be utilized for
 
metabolism and thermogenesis.
 
The core body temperatures in +/db and db/db animals were measured to determine
 
the effect ofT3treatment on thermogenesis. Core body temperatures of+/db mice were
 
greaterthan db/db animals which is whatis expected since diabetic animals exhibit impaired
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thermogenesis(Hummel e^a/. 1966). The temperatures ofboth +/db and db/db mice
 
increased with thyroid hormone treatment demonstrating thermogenic responses in both
 
phenotypes. These results are similar to those reported by Oh and Kaplan(1994)for the
 
phenotypically-related obese(pb/ob)mouse model. Obese ob/ob mice are hypothermic
 
making them similar to db/db animals (Oh and Kaplan 1994; Hummel al. 1966).
 
However,ob/ob mice are hypothyroid, meaning that T3 levels are decreased, yet are still
 
responsiveto T3. In contrast, mice are hyperthyroid but exhibit hyporesponsiveness
 
to the action ofthyroid hormone, which is indicative ofT3-resistance(Fehn et al. 1983,
 
1988). Thyroid hormone treatment elicits thermogenic responses in both ob/ob mice and
 
in db/db mice although db/db animals require supraphysiological doses to be effective.
 
Thus,T3increasesthe core bodytemperatures in both animal models. When the core body
 
temperatures were monitored throughout the ten day study, animals ofboth phenotypes
 
receiving T3 doses of200 and 500 ng/g BW,exhibited declining temperatures on days7
 
through 10. This,however,does not reflect a decrease inthermogenesis because lower core
 
body temperatures were accompanied by higher radiant temperatures. A reasonable
 
explanation for this observation is that the animals maintain their core body temperatures
 
by dissipating excess heat produced in response to T3 treatment as radiant heat. This
 
phenomenon represents normal T3-induced thermoregulation and accountsfor the changes
 
in temperature observed within these animals.
 
Radiant temperatures have not previously been reported for such studies, therefore
 
data from this study cannot be compared with published reports since this is a novel
 
approachto accountfor thermogenic activity. It does,however,account more accurately
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forincreasesin metabolism associated with T3treatment. Radianttemperatures in +/db and
 
db/db mice both increase withthyroid hormonetreatment. However,the increase in radiant
 
temperature was greatest in db/db animals. The increase in radiant temperatures might be
 
potentially explained by increased thermogenic capacity in response to increased GLUT4
 
expression in the plasma membranes ofmyocytes. This increase in GLUT4transporters
 
would account for increased glucose uptake by myocytes which would then utilize the
 
additional substrate in subsequent heat production(thermogenesis). Thyroid hormone also
 
hasbeen shownto stimulate membrane permeabilityto ions as well asinduce Na^/K^ pumps
 
in skeletal muscle, both ofwhich are believed to play a role in the thermogenic response
 
(Voldstedlund et al. 1995). The increase in thermogenic activity may also be associated
 
with higher C54oplasihic glucose concentrations due to Tj-induced GLUT4vesicular fusion
 
(integration)with the plasma membrane ofmyocytes. Thus,Tj-induced GLUT4expression
 
in the plasma membrane ofmyocytes may supportthermogenic activity.
 
Hyperglycemia is characteristic ofNIDDM individuals since glucose uptake is not
 
adequately handled dueto decreased insertion ofthe insulin-regulatable GLUT4transporter
 
into cell membranes. In the cuirent study,serum glucose levels were examined to determine
 
ifthyroid hormone treatmentimproved the glycemic status ofdb/db mice. Serum glucose
 
levels ofnormal animalsremained unchanged with T3treatment which suggests that T3 does
 
not affectthe normalglucose handling mechanism in insulin-responsive animals(Figure 17).
 
However,serum glucose concentrations in vehicle-treated db/db mice were approximately
 
50% greater than in ^/db animals, as could be expected for animals displaying insulin
 
resistance. Thyroid hormone decreased glucose concentrations about40% which suggests
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increased glucose utilization or restoration ofthe insulin response. Although still considered
 
hyperglycemic,the glycemic status ofdb/db animals wasimproved significantly with thyroid
 
hormonetreatment. This suggests thattissues were ableto take up glucose,however which
 
tissue specifically does this remainsto be determined and warrants further study.
 
One approach to this problem might be to evaluate substrate utilization which
 
accompanies the redistribution ofGLUT4. The respiratory quotient(RQ)is an indicator
 
ofwhich substrate isbeing utilized asthefuel source within the organism. In this study,the
 
respiratory quotientwas determined to see ifthyroid hormone treatment causes a shift in the
 
mefabolic substrate utilized by +/db and db/db animals. The RQ values of+/db mice
 
decreased in response to thyroid hormone treatment to levels suggestive ofa combination
 
ofcarbohydrates, proteins, and fats as substrate sources(Figure 18). However,theRQ in
 
db/db mice shifts from 0.87± 0.05, which indicates carbohydrate as the predominant
 
substrate sourceto 0.76±0.03 which indicates increased utilization offats, proteins, or both
 
as the metabolic substrates in response to thyroid hormone treatment. Evidence from a
 
previous study wherein the adipocyte volumes ofdb/db rmcQ decreased in response to T3
 
suggests that fats were the primary source of energy (Estrada unpublished results).
 
However,the decrease in serum glucose levels with T3 treatment in db/db mice from the
 
current study suggests that there is substantial uptake but not utilization as a metabolic
 
substrate, informal examination ofUvers m db/db mice suggests increased deposition offats
 
which may be attributedto increased hepatic glucose uptakeleading to enhanced lipogenesis
 
(data not shown). Although the glucose transporters in hepatocytes are not insulin­
regulatable, the lipogenic enzymes still remain inducible by T3 and may account for the
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 increased disposal ofglucosefrom the serum. However,theRQ values in the db/db mice
 
treated with supraphysiological doses ofthyroid hormone approached those ofvehicle-

treated +/db mice and suggest,once again,that normalization has taken place.
 
TheRQ values indicating a shift to fat catabolism do not supportthe observation of
 
increased membrane-associated GLUT4 transporters in myocytes facilitating increased
 
cellular glucose uptake and utilization. An explanation for increased GLUT4 associated
 
with the plasma membrane in the absence ofglucose utilization may be that the GLUT4
 
transporter-containing vesicles dock with the plasma membrane and are isolated with plasma
 
membrane fractions. The docked vesicles, however, may not be fused and therefore the
 
GLUT4transporters are not integrated into the plasma membrane. Thus,glucose uptake
 
by myocytes cannot be facilitated since the GLUT4transporter is not inserted correctly.
 
However,the energy by which thermogenesis is fueled is probably provided by fatty acids,
 
anidea which is supported by anRQ shift indicating fat catabolism,in conjunction with an
 
increase in radiant temperatures. The mechanism by which the vesicles containing the
 
GLUT4glucose transportersfiise withthe plasma membrane warrants further investigation
 
to see ifthat step within the trafficking mechanism is defective within NIDDM subjects.
 
This study has demonstrated reduced total GLUT4 expression in adipocytes and
 
decreased GLUT4transporters associated with the plasma membranes ofmyocytes ofdb/db
 
mice but an increases in these quantities in response to exogenous T3. The current study
 
also demonstrated that T3treatmentinducesGLUT4glucose transporter redistribution from
 
the cytoplasm to the plasma membrane of adipocytes and myocytes in db/db mice.
 
Observations from adipocytes are consistent with studies by Zorzano et al.(1996),Rahn
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eta/(1989),and Berger etal.(1989). Gibbseta/.(1995)dluded to a trafFickirig problem
 
in GLUT4transgenic db/db mice in which GLIJT4 pverexpression could cpmpensate for
 
a trafficking defect. This is consistent with the proportionalfusion from the cytoplasm to
 
the plasma membrane demonstrated in this study,but T3 corrects the GLUT4 distribution
 
in mice. Thetransgenict^/£/& mice showed a marked decrease in hyperglycemia due
 
to increased glucose transport. However,Gibbs et al.(1995)did not evaluate the cellular
 
GLUT4 distribution in all tissues oftransgenic mice and the potential consequences of
 
increased glucose disposal by tissues that typically do not express the GLUT4transporter.
 
More recently, Torrance et al. (1997) showed that T3 regulates GLUT4 transporter
 
expression atthe transcriptional levelin hypothyroid rats made hyperthyroid. Although not
 
pointed out by the authors, T,was shown to regulate GLUT4 transporter translocation
 
because distribution differences in GLUT4 transporters are observed in response to T,
 
administration. The results of the current study indicate that GLUT4 transporter
 
translocation from the cytoplasm to the plasma membrane is regulated by T3in db/db mice
 
and isthe first report ofsuch regulation. The increased thermogenic response observed in
 
this study parallels increased numbers ofGLUT4transporters in the plasma membrane of
 
myocytes but the RQ values do not support carbohydrate utilization as the metabolic
 
substrateforthethermogenicresponse. However, decreased serum glucose levels in dh/db
 
micein responseto T3treatment indicates that glucose is taken up but is not utilized asthe
 
metabolic substrate for thermogenesis. The liver may take up the glucose via GLUT2
 
transporters which are not insulin-regulated. Absorbed glucose maythen be converted to
 
fat and stored away. Ifthis isthe case,this mayimply that the GLUT4glucose transporters
 
glucose uptake. Theenergyto drive the Observed metabolic responses is likely supplied by
 
fats. This study suggests amodel wherein high doses ofT3 overcome thyroid hormone
 
resistance in the db/db mouse and restore GLUT4transporter translocation.
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